Supplementary Information

New conformationally flexible and recyclable aryl iodine catalysts from inexpensive chiral source for asymmetric oxidations

Hai-Jie Zhou,¹ Yi-Ping Yao,¹ Tonghui Zhang,⁵ Biao Chen,¹ Xu Wang,¹ Jie Zeng,⁵ Hang Zhao,¹ Jian-Ai Chen,¹ Xiao Xiao,^{*,1} Fen-Er Chen^{*,1,2,3,4,5}

¹Institute of Pharmaceutical Science and Technology, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, P. R. China

²College of Chemistry and Chemical Engineering, Jiangxi Normal University, Nanchang, 330022, P. R. China

³Engineering Center of Catalysis and Synthesis for Chiral Molecules, Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Fudan University, Shanghai 200433, P. R. China ⁴Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, P. R. China

⁵Pharmaceutical Research Institute, Wuhan Institute of Technology, Wuhan 430205, P. R. China.

Table of Contents

1	. Supplementary methods
2	. Synthesis of the starting materials
3	. Catalysts, solvent and temperature optimization
4	. General procedure and spectra data of catalyst 10
	4.1 General procedure for synthesis of catalyst starting from (1 <i>S</i> ,2 <i>S</i>)-ANP
	4.1.1 General procedure for synthesis of intermediate 11 10
	4.1.2 General procedure for synthesis of silicon-based catalysts
	4.1.3 General procedure for synthesis of ester catalysts
	4.1.4 General procedure for synthesis of ether-substituted catalysts
	4.1.5 General procedure for synthesis of 2-iodo-5-substituted catalysts
	4.2 Hundred grams scale procedure for synthesis of intermediate 11
	4.3 General procedure for synthesis of catalyst starting from <i>D</i> -threonine
	4.4 General procedure for catalyst of the N-H bond of the amide moiety changed to N-Me
	bond
	4.5 Characterization of catalysts and intermediates

5. General procedure of recycle experiments in oxidative dearomatization	. 49
6. Gram scale operation	. 51
7. Spectra data of substrate.	. 52
7.1 Characterization of enantioselective oxidative dearomatization	. 52
7.2 Characterization of oxidative spirolactonization	. 72
7.3 Characterization of direct C(sp ²)-H/C(sp ³)-H cross-coupling	. 78
7.4 Characterization of oxidative fluorination of keto esters.	. 84
8. Investigation of the significance for H-bond interactions and tunable chiral pocket	. 94
9. Possible mechanism of the reactions	100
9.1 Possible mechanism and DFT calculation of the enantioselective oxidative dearomatization.	100
9.2 Possible mechanism of the asymmetric spirocyclization reaction	102
9.3 Possible mechanism of the direct C(sp ²)-H/C(sp ³)-H oxidative cross-coupling	103
9.4 Possible mechanism of the asymmetric oxidative fluorination of keto esters	104
10. Reference	105
11. X-ray crystallography analysis	108
12. ¹ H, ¹³ C, ¹⁹ F spectrum of compounds	113
12.1 NMR spectra of intermediates and catalyst	113
12.2 NMR spectra of product	162
12.2.1 Spectrum of enantioselective oxidative dearomatization	162
12.2.2 Spectrum of oxidative spirolactonization	187
12.2.3 Spectrum of direct C(sp ²)-H/C(sp ³)-H cross-coupling	193
12.2.4 Spectrum of oxidative fluorination of keto esters	199

1. Supplementary methods

General information. All experiments were conducted under air atmosphere unless otherwise noted. ¹H and ¹³C NMR spectra were recorded on a Bruker AscendTM 400 (400 MHz) spectrometer. Chemical shifts were reported in parts per million (ppm), and the residual solvent peak was used as an internal reference: ¹H (CDCl₃ δ 7.26; DMSO-d⁶ δ 2.50), ¹³C (CDCl₃ δ 77.16; DMSO-d⁶ δ 39.5). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constants (Hz) and integration. For thin layer chromatography (TLC), Huanghai precoated TLC plates (GF254) were used, and compounds were visualized with a UV light at 254 nm. High resolution mass spectra (HRMS) were obtained on an Agilent 1290II-6545 spectrometer. Optical rotations were recorded on a Rudolph Research Analytical Autopol I automatic polarimeter. Enantiomeric excesses (ee) were determined by HPLC analysis on Agilent HPLC units; column of Chiralcel OD-H, Chiralpak AD-H or AS-H was used. Melting point (MP) was obtained on Hanon MP-430.Column chromatography was performed with silica gel (200-300 mesh ASTM). Unless otherwise noted, commercially available reagents purchased from Adamas-beta, TCI, Rhawn or Energy Chemical and were used as received.

Computational details

All the species are fully optimized at the M06-2X level^[1], the 6-31G(d,p)^[2] basis set is used for H, C, N, O atom, and the LANL2D2 ECP basis set^[3] is used for I atom. Frequency analyses are performed at the same level to confirm that the characteristics of the structures are minima (without imaginary frequencies) or transition states (only one imaginary frequency). Calculations of the intrinsic reaction coordinates (IRC)^[4-5] are calculated to ensure that the transition states indeed have connected two minima. The single-point energies calculated at M06-2X Level^[1], the 6-311++G(d,p)^[2] level basis set is used for H, C, N, O atom. The single-point energies are added to the Gibbs free energy correction to obtain the Gibbs free energies (ΔG). All these calculations are performed with Gaussian 16 program^[6].

2. Synthesis of the starting materials

1) 1-naphthol carboxylic acid **12a-12l** were synthesized according to the literature^[7].

2) 2-naphthol carboxylic acid **12m-12o** were synthesized according to the literature^[8].

3) 1-naphthol carboxylic alcohol were synthesized according to the literature^[9].

4)1-hydroxy-*N*-aryl-2-naphthamide derivatives **15a-15f** were synthesized according to the literature^[10].

5) Anilide derivatives **17a-17f** were synthesized according to the literature^[11].

6) Keto esters derivatives **19a-19k** were synthesized according to the literature^[12].

3. Catalysts, solvent and temperature optimization

	OF	н Соон 12	Cat (5- ^m CPBA CH ₂ Cl ₂ ,	15 mol%) (1.5 equiv.) Temp., 24 h	(0 13a	≻o	ТВІ	HN DPSO Cat	$\frac{\text{Mes}}{\text{O}} \qquad \text{Me}$	s NH UOTBD 4)	PS
Entry	Cat (mol%)	Temp. (°C)	Solvent	Yield (%)	ee (%)	Enti	y Cat	(mol%)	Temp. (°C)	Solvent	Yield (%)	ee (%)
1	Cat-1 (15)	-30	CH ₂ Cl ₂	45	85	11	Cat-	33 (15)	0	CH ₂ Cl ₂	80	92
2	Cat-2 (15)	-30	CH_2CI_2	66	79	12	Cat-	8 (15)	-20	toluene	77	96
3	Cat-6 (15)	-30	CH_2CI_2	56	86	13	Cat-	8 (15)	-20	EtOAc	44	87
4	Cat-7 (15)	-30	CH_2CI_2	72	91	14	Cat-	8 (15)	-20	CH ₂ Cl ₂ + EtOH ^d	92	98
5	Cat-8 (15)	-30	CH_2CI_2	77	98	15	Cat-	8 (10) ^e	-20	CH ₂ Cl ₂ + EtOH ^d	80	98
6	Cat-9 (15)	-30	CH_2CI_2	52	90	17	Cat-	8 (5) ^f	-20	CH ₂ Cl ₂ + EtOH ^d	72	98
7	Cat-11 (15)	-30	CH ₂ Cl ₂	47	86	18	Cat-	8 (15)	-20	CH ₂ Cl ₂ + EtOH ^g	92	96
8	Cat-21 (15)	-30	CH ₂ Cl ₂	35	75	19	Cat-	41 (15)	-20	CH ₂ Cl ₂	trace	
9	Cat-8 (15)	-20	CH ₂ Cl ₂	82	98	20	Cat-	12 (15)	-20	CH ₂ Cl ₂	70	93
10	Cat-8 (15)	0	CH_2CI_2	87	96	21	Cat-	42 (15)	-20	CH ₂ Cl ₂	83	87

Supplementary Table 1. Optimization of enantioselective oxidative dearomatization^{a,b,c}

^a**12** (0.2 mmol), **Cat-8** (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were stirred in CH₂Cl₂ (10 mL) at -30 to 0 °C for 24 h. ^bIsolated yield. ^cThe *ee* value was determined by chiral HPLC. ^dEtOH (1 mmol, 5 equiv.) was added. ^e**Cat-8** (0.02 mmol, 10 mol%) was added. ^f**Cat-8** (0.01 mmol, 5 mol%) was added. ^gCH₂Cl₂ (5 mL), and EtOH (1 mmol, 5 equiv.) was added.



To a Schlenk tube containing **Cat-8**, ^{*m*}CPBA (0.3 mmol, 1.5 equiv.), and EtOH were added CH_2Cl_2 (10 mL) and **12** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 0 to -20 °C for 24 hours, which was then quenched in the sequence of saturated $Na_2S_2O_3$ and $NaHCO_3$ aqueous solution. The organic layer was extracted by CH_2Cl_2 and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.

	NMe År	Cat (15 mol%) ^m CPBA (1.3 equiv.) TFE (50 equiv.) H ₂ O (10 equiv.) MeNO ₂ , Temp.		Me R ²			
Entry	R ¹	R ²	R ³	т	Yield (%)	Time	ee (%)
1	Mes	COMes	Н	-20 °C	30	2 day	56
2	Mes	COMes	Me	-20 °C	27	2 day	53
3	Mes	COMes	COOMe	-20 °C	33	2 day	55
4	Mes	COMes	3,5-di(CF ₃)C ₆ H ₃	-20 °C	25	2 day	53
5	Mes	TBDPS	Н	-20 °C	35	2 day	70
6	Ad	TBDPS	Н	-20 °C	39	2 day	96
7	4-OMeC ₆ H ₄	TBDPS	Н	-20 °C	36	2 day	85
8	$4-NO_2C_6H_4$	TBDPS	Н	-20 °C	42	2 day	96
9	$4-MeC_6H_4$	TBDPS	Н	-20 °C	37	2 day	79
10	4- ^t BuC ₆ H ₄	TBDPS	н	-20 °C	40	2 day	87
11	$4-NO_2C_6H_4$	TBDPS	Н	-20 °C	55	5 day	91
12	$4-NO_2C_6H_4$	TBDPS	Н	0 °C	61	2 day	91
13	$4-NO_2C_6H_4$	TBDPS	Н	-10 °C	57	3 day	94
14 ^d	$4-NO_2C_6H_4$	TBDPS	Н	-10 °C	43	3 day	92
15 ^e	$4-NO_2C_6H_4$	TBDPS	Н	-10 °C	39	3 day	91

Supplementary Table 2. Optimization of enantioselective oxidative spirolactonization^{a,b,c}

Conditions: ^a15 (0.2 mmol), **Cat-9** (0.03 mmol, 15 mol%), ^mCPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.) and H₂O (2 mmol, 10 equiv.) were stirred in MeNO₂ (3 mL) at -10 °C. ^bIsolated yield. ^cThe *ee* value was determined by chiral HPLC. ^dWithout H₂O. ^eWithout TFE.

To a Schlenk tube containing **Cat-9** (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.), H₂O (2 mmol, 10 equiv.) and MeNO₂ (3 mL) were added **15** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at -10 °C for 72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was extracted by CH₂Cl₂ and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.

MeN MeN	NMe -	Cat (15 mol%) ⁿ CPBA (2.6 equiv.) TFA (3.0 equiv.) slovent, 25 °C	Me N N N Me 18	R ¹ COHN R ² O	R ³	
Entry	R ¹	R ²	R ³	Yield (%)	Solvent	ee (%)
1	Mes	COMes	Н	23	MeCN	4
2	Mes	COMes	Ме	27	MeCN	0
3	Mes	COMes	COOMe	35	MeCN	0
4	Mes	COMes	3,5-di(CF ₃)C ₆ H ₃	20	MeCN	0
5	Mes	TBDPS	Н	60	MeCN	7
6	NH(4-Me)C ₆ H	H ₄ TBDPS	Н	72	MeCN	74
7 ^d	NH(4-Me)C ₆ H	H ₄ TBDPS	Н	N.R.	MeCN	00
8	NH(4-Me)C ₆ H	H ₄ TBDPS	Н	42	Benzonitrile	50
9	NH(4-Me)C ₆ H	H ₄ TBDPS	Н	37	Butyronitrile	83
10	$4-MeC_6H_4$	TBDPS	Н	40	Butyronitrile	84
11	4- ^t BuC ₆ H₄	TBDPS	Н	43	Butyronitrile	77
12	^t Bu	TBDPS	Н	52	Butyronitrile	86
13	^t Bu	TBDPS	Н	72	MeCN	84
14 ^e	^t Bu	TBDPS	Н	72	MeCN	90

Supplementary Table 3. Optimization of enantioselective direct C(sp²)-H/C(sp³)-H cross-coupling.^{a,b,c,d}

Conditions: ^a17 (0.2 mmol), **Cat-3** (0.03 mmol, 15 mol%), ^mCPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) were stirred in MeCN (3 mL) at 25 °C for 16 h. ^bIsolated yield. ^cThe *ee* value was determined by chiral HPLC.^d0 °C. ^e H₂O (3.0 equiv.) was added.

To a Schlenk tube containing **Cat-3** (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) and H₂O and MeCN (3 mL) were added **17** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 25 °C for 16 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was extracted by EtOAc and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.

CI	CO₂Me Cat (15 mo ^m CPBA (1.2 e) Et ₃ N•3HF (10 CHCl ₃ , 25	l%) equiv.) °C		
19		20	Ar =	4-NO ₂ C ₆ H ₄
Entry	R ¹	R ²	Yield (%)	ee (%)
1	н	COMes	55	44
2	2,6-diMe	COMes	57	61
3	3,5-diCF ₃	COMes	52	54
4	3,5-diCl	COMes	60	50
5	2,4,6-triMe	COMes	55	60
6	4-NO ₂	COMes	54	33
7	2,4,6-triCl	COMes	59	65
8 ^d	2,4,6-triCl	COMes	27	67
9	2,4,6-triBr	COMes	59	72
10	2,4,6-triCl	C(C ₆ H ₅) ₃	59	80
11	2,4,6-triBr	$C(C_{6}H_{5})_{3}$	57	90

Supplementary Table 4. Optimization of enantioselective oxidative fluorination of keto esters.^{a,b,c}

^a19 (0.2 mmol), **Cat-38** (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.3 mmol, 1.5 equiv.), and Et₃N·3HF (2 mmol, 10 equiv.) were stirred in CHCl₃ (8 mL) at 25 °C for 24 h. ^bIsolated yield. ^cThe *ee* value was determined by chiral HPLC. ^dDPIEA·3HF (2 mmol, 10 equiv.) was added instead of Et₃N·3HF.

To a Teflon tube containing β -ketoesters **19** (0.20 mmol, 1.0 equiv.), **Cat-38** (0.03 mmol, 15 mol%), and CHCl₃ (8 mL) were added amine HF (2 mmol, 10 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) in turn, the reaction mixture was stirred at 25 °C for 24-72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was extracted by CH₂Cl₂ and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.

4. General procedure and spectra data of catalyst

4.1 General procedure for synthesis of catalyst starting from (1*S*,2*S*)-ANP.

4.1.1 General procedure for synthesis of intermediate 11



According to a modified literature procedure,^[13] to a 1-L round bottom flask containing (1*S*,2*S*)-ANP (330 mmol, 1.0 equiv.) were dissolved in THF (500 mL) at 0 °C, Boc₂O (346.5 mmol, 1.05 equiv.) was added dropwise and reaction mixture was allowed to stir at ambient temperature until full conversion of (1*S*,2*S*)-ANP, as shown by TLC. The organic layers were concentrated under vacuum. The crude product was recrystallized using ethyl acetate to afford the **6** (93.6 g, 91% yield) in a pure form.



According to a modified literature procedure,^[14] the cyclic sulfamidate was synthesized from the **6** by a three-step sequence: Silicon-based protection/Cyclization/NaIO₄ oxidation.

Step 1: the corresponding **6** (300 mmol, 1.0 equiv.) and imidazole (330 mmol, 1.3 equiv.) were dissolved in dry CH_2Cl_2 in a dry round bottom flask. TBDPSCl (315 mmol, 1.05 equiv.) dissolved in dry CH_2Cl_2 was added dropwise at 0 °C, and then the reaction mixture was allowed to stir at room temperature until TLC indicated completely consumed of the **6**. After completion of the reaction, water was added. The reaction mixture was extracted with CH_2Cl_2 (3x) and washed with brine (1x). The combined organic layers were dried over Na_2SO_4 , the solvent was evaporated under vacuum. The crude residue was directly used in the next step without further purification.

Step 2: To the dry three-necked flask, the **7** (1.0 equiv.) and imidazole (3.0 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to $-30 \,^{\circ}$ C. Et₃N (2.4 equiv.) was added dropwise and the resulting mixture was stirred at $-30 \,^{\circ}$ C for 30 min. Then the SOCl₂ was added dropwise and the resulting mixture was stirred at $-30 \,^{\circ}$ C for 3 h until TLC indicated completely consumed of the **7**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 3: To the three-necked flask, **SI-1** was dissolved in MeCN and water (1:1), $RuCl_3 \cdot 3H_2O$ (1 mol%) and $NaIO_4$ (1.1 equiv.) were added sequentially and the resulting mixture was stirred at room temperature for 4 h until TLC indicated completely consumed of the **SI-1**. The MeCN was concentrated under vacuum. Water was added and the reaction mixture was extracted with ethyl acetate (3x). The organic layers were combined and dried over Na_2SO_4 , filtered, and concentrated under

vacuum. The crude product is recrystallized using MeOH to afford the **10** (159 g, 86% yield in three steps) in a pure form.



To the dry three-necked flask tube, the **8** (1.0 equiv., 130 mmol, 30.68 g) was dissolved in dry DMF (300 mL) under nitrogen before being cooled to 0 °C. NaH (2.4 equiv., 312 mmol, 12.48 g) was added and the resulting mixture was stirred at 0 °C for 30 min. Then the **10** (2.0 equiv., 260 mmol, 159 g) dissolved in dry DMF (500 mL) was added dropwise and the resulting mixture was stirred at 0 °C for 4 h until TLC indicated completely consumption of the **9**. The reaction was quenched with 1N HCl. Water is further added to the system to precipitate the solids. Crude **Cat-1** (258 g) was isolated by filtration which was directly used in the next step without further purification.



To the dry three-necked flask, the crude **Cat-1** (258 g) was dissolved in dry CH_2Cl_2 (120 mL). TFA (30 mL) was dropwise at 0 °C and the resulting mixture was stirred at room temperature for 2 h until TLC indicated completely consumed of the **Cat-1**. The reaction was quenched with a saturated solution of NaHCO₃. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude product is recrystallized using MeOH to afford the **11** (106 g, 74% yield in two steps) in a pure form.

4.1.2 General procedure for synthesis of silicon-based catalysts



Method 1: To the dry three-necked flask, the aryl iodine intermediate **11** and Et₃N (2.3 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. R¹COCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated completely consumed of the aryl iodide. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding Chiral aryl iodine catalyst in a pure form.

Method 2: To the dry three-necked flask, the aryl iodide intermediates **11** and Et₃N (2.3 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. R^2SO_2Cl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the aryl iodide. The reaction was quenched with water. The organic layer was separated and the aqueous layer was

extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding Chiral aryl iodine catalyst in a pure form.

Method 3: To the dry three-necked flask, the aryl iodide intermediates **11** and Et₃N (2.3 equiv.) were dissolved in dry CH_2Cl_2 under nitrogen before being cooled to 0 °C. Isocyanates (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the aryl iodide. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding Chiral aryl iodine catalyst in a pure form.

4.1.3 General procedure for synthesis of ester catalysts



Step 1: To a round bottom flask containing the **Cat-1** (1.0 equiv.) and dry THF at room temperature was added TBAF (3.0 equiv.) dropwise. The reaction mixture was stirred for 3 h. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 2: To the dry three-necked flask, the **SI-2** and Et₃N (2.5 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. MesCOCl (2.2 equiv.) or AcCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the **SI-2**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding **SI-3** in a pure form.

Step 3: To the dry three-necked flask, the **SI-3** was dissolved in dry CH_2Cl_2 . TFA was dropwise at 0 °C and the resulting mixture was stirred at room temperature for 2 h until TLC indicated completely consumed of the **SI-3**. The reaction was quenched with a saturated solution of NaHCO₃. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The residue was recrystallized using MeOH to afford the **SI-4** in a pure form.

The general procedure for synthesis of ester catalysts from **SI-4** is same to synthesis of silicon-based catalysts.

4.1.4 General procedure for synthesis of ether-substituted catalysts



Step 1: To a round bottom flask containing corresponding silicon-based catalysts (1.0 equiv.) and dry THF at room temperature was added TBAF (3.0 equiv.) dropwise. The reaction mixture was stirred for 3 h. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 2: To the dry three-necked flask, the **SI-5** and Et₃N (2.5 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. Ph₃CCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the **SI-5**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding ether catalysts in a pure form.

4.1.5 General procedure for synthesis of 2-iodo-5-substituted catalysts



The general procedure was same to the procedure of synthesis of compound **11**.



4.2 Hundred grams scale procedure for synthesis of intermediate 11

Supplementary Figure 1. Flowchart of hundred grams scale synthesis of intermediate 11



4.3 General procedure for synthesis of catalyst starting from *D*-threonine

According to a modified literature procedure,^[15] **SI-4** was synthesized from the *D*-threonine by a three-step sequence: Esterification/Amino protection/NaBH₄ reduction.

Step 1: To a 500-mL round bottom flask containing *D*-threonine (11.9 g, 100 mmol, 1.0 equiv.) and MeOH (200 mL) at 0 °C was added Thionyl chloride (150 mmol, 1.5 equiv.) dropwise. The reaction mixture was allowed to reflux overnight at 80 °C. The organic layers were concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 2: The **SI-6** (1.0 equiv.) and NaHCO₃ (120 mmol, 1.2 equiv.) were dissolved in MeOH and water (1:1) before being cooled to 0 °C, Boc₂O (120 mmol, 1.2 equiv.) was added dropwise and the reaction mixture was allowed to stir at ambient temperature until full conversion of the **SI-6**, as shown by TLC. The MeOH was concentrated under vacuum. Water was added and the reaction mixture was extracted with CH_2Cl_2 (3x). The organic layers were combined and dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 3: To a 500-mL round bottom flask containing **SI-7** (1.0 equiv.) and MeOH at 0 $^{\circ}$ C was added NaBH₄ (300 mmol, 3.0 equiv.) portion wise. The reaction mixture was allowed to stir at 0 $^{\circ}$ C until TLC indicated full conversion of the **SI-7**. The

MeOH was concentrated under vacuum. Water was added and the reaction mixture was extracted with ethyl acetate (5x). The organic layers were combined and dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was subjected to column chromatography on silica gel (PE:EA 1:1) to afford the **SI-8** in a pure form. (15.4 g, 75% yield in three steps).



Step 4: The corresponding **SI-4** (15.4 g, 75 mmol, 1.0 equiv.) and imidaloze (6.12 g, 90 mmol, 1.2 equiv.) were dissolved in dry CH_2Cl_2 in a dry round bottom flask. TBDPSCl (21.5 mL, 82.5 mmol, 1.1 equiv.) dissolved in dry CH_2Cl_2 was added dropwise at 0 °C, and then the reaction mixture was allowed to stir at room temperature until TLC indicated full conversion of the **SI-8**. After completion of the reaction, water was added. The reaction mixture was extracted with CH_2Cl_2 (3x) and washed with brine (1x). The combined organic layers were dried over Na_2SO_4 , the solvent was evaporated under vacuum. The crude residue was directly used in the next step without further purification.



Step 5: According to a modified literature procedure,^[] to the dry three-necked flask, the **SI-9** (1.0 equiv.) and imidazole (15.3 g, 225 mmol, 3.0 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to -40 °C. Et₃N (25 mL, 180 mmol, 2.4 equiv.) was added dropwise and the resulting mixture was stirred at -40 °C for 30 min. Then the SOCl₂ (6.6 mL, 90 mmol, 1.2 equiv.) was added dropwise and the

resulting mixture was stirred at -40 °C for 4 h until TLC indicated full conversion of the **SI-9**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 6: To the three-necked flask, **SI-10** was dissolved in MeCN and water (1:1), RuCl₃· $3H_2O$ (155 mg, 0.75 mmol, 1 mol%) and NaIO₄ (17.8 g, 82.5 mmol, 1.1 equiv.) were added sequentially and the resulting mixture was stirred at room temperature for 4 h until TLC indicated consumption of the **SI-10**. The MeCN was concentrated under vacuum. Water was added and the reaction mixture was extracted with ethyl acetate (3x). The organic layers were combined and dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was subjected to column chromatography on silica gel (PE:EA 10:1) to afford the **SI-10** in a pure form. (32.19 g, 85% yield)



Step 7: To the dry three-necked flask, the **8** (2.36 g, 10 mmol, 0.5 equiv.) was dissolved in dry DMF under nitrogen before being cooled to 0 °C. NaH (960 mg, 24 mmol, 1.2 equiv.) was added and the resulting mixture was stirred at 0 °C for 30 min. Then the **SI-11** (10.1 g, 20 mmol, 1.0 equiv.) dissolved in dry DMF was added dropwise and the resulting mixture was stirred at 0 °C for 4 h until TLC indicated consumption of the 2-iodobenzene-1,3-diol. The reaction was quenched with 1N HCl. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was subjected to column

chromatography on silica gel (PE:EA 6:1) to afford the **SI-12** (8.5 g, 78% yield) in a pure form.



Step 8: To the dry three-necked flask, the **SI-12** (8.5 g, 7.8 mmol, 1.0 equiv.) was dissolved in dry CH_2Cl_2 . TFA (10.0 equiv.) was added and the resulting mixture was stirred at room temperature for 2 h until TLC indicated consumption of the **SI-12**. The reaction was quenched with a saturated solution of NaHCO₃. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was subjected to column chromatography on silica gel (PE:EA 1:1) to afford the **SI-13** (6.6 g, 95% yield) in a pure form.



Step 9: To the dry three-necked flask, the **SI-13** and Et_3N (2.3 equiv.) were dissolved in dry CH_2Cl_2 under nitrogen before being cooled to 0 °C. R¹COCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the **SI-13**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was recrystallized by CH_2Cl_2 and hexane to afford the corresponding the **Catalyst** a pure form.

4.4 General procedure for catalyst of the *N*-H bond of the amide moiety changed to *N*-Me bond.



General procedure: To the dry three-necked flask tube, the corresponding *N*-H catalyst (1.0 equiv.) was dissolved in dry DMF under nitrogen before being cooled to 0° C. NaH (2.2 equiv.) was added and the resulting mixture was stirred at 0 °C for 30 min. Then the CH₃I (2.5 equiv.) was added dropwise and the resulting mixture was allowed to stirred at room temperature for 4 h until TLC indicated completely consumption of the starting material. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was subjected to column chromatography on silica gel to afford the *N*-Me catalyst in a pure form.

4.5 Characterization of catalysts and intermediates.



9 was isolated from mitsunobu reaction as colorless oil. DIAD (452 uL, 2.3 mmol, 2.3 equiv.) was dropwise to **8** (236 mg, 1 mmol, 1 equiv.), **7** (550 mg, 2.2 mmol, 2.2 equiv.) and PPh₃ (707 mg, 2.7 mmol, 2.7 equiv.) in THF at

0 °C. 9 (316 mg, 27% yield) was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹H NMR (400 MHz, CDCl₃) 7.97 (d, J = 8.9 Hz, 2H), 7.49 – 7.43 (m, 2H), 7.34 – 7.21 (m, 8H), 7.13 (dd, J = 8.9, 6.0 Hz, 2H), 3.69 – 3.60 (m, 2H), 3.07 (dd,

J = 11.0, 7.6 Hz, 1H), 3.03 - 2.96 (m, 1H), 1.38 (s, 9H), 0.87 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 161.6, 147.3, 142.2, 135.6, 135.3, 132.8, 132.7, 129.8, 129.8, 128.5, 127.7, 127.6, 123.3, 82.0, 60.9, 45.0, 42.4, 28.0, 27.9, 27.9, 26.7, 19.1. HRMS (ESI) m/z Calcd for [C₃₀H₃₆N₂O₅Si, M+Na]⁺: 555.2286, found 555.2281.



The crude product is recrystallized using MeOH to afford the **10** (159 g, 86% yield in three steps) in a pure form. **MP:** 128.7-130.1 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.16-8.10 (m, 2H), 7.59 (m, 4H), 7.47-7.29 (m, 8H), 5.76 (d, *J* = 5.7 Hz, 1H), 4.16

(dd, J = 10.3, 5.0 Hz, 2H), 3.69-3.58 (m, 1H), 1.44 (s, 9H), 1.04 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 148.7, 148.2, 141.0, 135.7, 135.6, 132.4, 132.1, 130.4, 130.3, 128.2, 128.1, 128.0, 127.7, 124.3, 86.0, 79.1, 64.6, 59.6, 27.9, 26.8, 19.3. HRMS (ESI) m/z Calcd for [C₃₀H₃₆N₂O₈SSi, M+H]⁺: 635.1854, found 635.1846.



The crude product is recrystallized using MeOH to afford the **11** (106 g, 74% in two steps) in a pure form. **MP:** 206.3-208.7 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.7 Hz, 4H), 7.57-7.48 (m, 8H), 7.45-7.39 (m, 4H), 7.35-7.24 (m, 8H), 7.21-7.16 (m, 4H), 6.73 (t, *J* = 8.3 Hz, 1H),

5.97 (d, J = 8.3 Hz, 2H), 5.31 (d, J = 5.8 Hz, 2H), 3.88 (dd, J = 10.2, 6.1 Hz, 2H), 3.61 (dd, J = 10.2, 5.0 Hz, 2H), 3.37-3.28 (m, 2H), 0.96 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 156.9, 147.8, 145.3, 135.7, 135.6, 133.1, 133.1, 130.0, 129.9, 129.7, 128.1, 128.0, 127.9, 123.9, 106.5, 80.9, 79.8, 64.9, 57.8, 27.0, 19.4. **HRMS** (ESI) m/z Calcd for [C₅₆H₆₁IN₄O₈Si₂, M+H]⁺: 1101.3145, found 1101.3154.

Optical Rotation: $[\alpha]_{b}^{5}$ 8.3 (c = 1.0, CHCl₃). >99.9% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 5.180 min for major isomer, t_R = 8.713 min for minor isomer).





SI-13 was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 5/1) as colorless oil. ($R_f = 0.5$, petroleum ether/ethyl acetate =

5/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.70-7.60 (m, 8H), 7.46-7.29 (m, 12H), 7.15 (t, *J* = 8.3 Hz, 1H), 6.44 (d, *J* = 8.4 Hz, 2H), 4.61-4.51 (m, 2H), 3.90-3.77 (m, 4H), 3.26-3.16 (m, 2H), 1.31 (d, *J* = 6.3 Hz, 6H), 1.06 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 157.8, 135.7, 135.7, 133.5, 133.4, 129.9, 129.8, 129.6, 127.9, 127.9, 106.1, 81.8, 76.2, 65.5, 56.7, 27.0, 19.4, 15.2. **HRMS** (ESI) m/z Calcd for [C₄₆H₅₉IN₂O₄Si₂, M+H]⁺: 909.2950, found 909.2971.



The crude **Cat-1** was purified by MeOH and H₂O as yellow solid. **MP:** 108.0- 111.2°C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.2 Hz, 4H), 7.61-7.47 (m, 12H), 7.36 (dd, *J* = 26.7, 7.3 Hz, 8H), 7.21 (t, *J* = 7.5 Hz, 4H), 6.84 (t, *J* = 8.2

Hz, 1H), 6.05 (d, J = 8.3 Hz, 2H), 5.44 (d, J = 6.3 Hz, 2H), 5.01 (d, J = 9.1 Hz, 2H), 4.30 (dd, J = 10.6, 5.1 Hz, 2H), 4.22-4.17 (m, 2H), 3.89-3.79 (m, 2H), 1.32 (s, 18H), 1.03 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 157.1, 155.2, 147.7, 145.3, 135.6, 135.6, 132.9, 132.8, 130.0, 129.9, 129.7, 127.9, 127.9, 127.8, 123.8, 106.5, 79.9, 79.6, 79.5, 62.3, 57.1, 28.3, 27.0, 19.3. **HRMS** (ESI) m/z Calcd for [C₆₆H₇₇IN₄O₁₂Si₂, M+H]⁺: 1323.4013, found 1323.4023.



Cat-2 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and acetyl chloride (173.8 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to

precipitate the title compound (1.086 g, 0.9 mmol, 90%) as a white solid. **MP:** 188.0-183.2°C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.04 (d, *J* = 8.6 Hz, 4H), 7.50-7.45 (m, 8H), 7.41 (d, *J* = 8.5 Hz, 4H), 7.34-7.27 (m, 4H), 7.26-7.17 (m, 8H), 6.75 (t, *J* = 8.3 Hz, 1H), 5.95 (d, *J* = 8.4 Hz, 2H), 5.80 (d, *J* = 8.7 Hz, 2H), 5.38 (d, *J* = 5.4 Hz, 2H), 4.45-4.37 (m, 2H), 4.22 (dd, *J* = 11.0, 6.2 Hz, 2H), 3.72 (dd, *J* = 10.9, 3.3 Hz, 2H), 1.76 (s, 6H), 0.94 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 169.9, 157.2, 147.7, 144.9, 135.6, 132.9, 132.8, 130.1, 130.0, 130.0, 128.0, 128.0, 127.5, 123.9, 106.8, 79.7, 79.5, 61.8, 56.0, 26.9, 23.3, 19.3. **HRMS** (ESI) m/z Calcd for [C₆₀H₆₅IN₄O₁₀Si₂, M+H]⁺: 1207.3176, found 1207.3190.



Cat-3 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and pivaloyl chloride (265.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH and water to precipitate the title compound (1.078 g,

0.85 mmol, 85%) as a white solid. **MP:** 118.1-118.7 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.13 (d, J = 8.7 Hz, 4H), 7.57-7.48 (m, 12H), 7.41-7.37 (m, 2H), 7.36-7.28 (m, 6H), 7.25-7.19 (m, 4H), 6.84 (t, J = 8.3 Hz, 1H), 6.23 (d, J = 8.3 Hz, 2H), 6.06 (d, J = 8.4Hz, 2H), 5.48 (d, J = 6.2 Hz, 2H), 4.54-4.45 (m, 2H), 4.35 (dd, J = 10.8, 5.4 Hz, 2H), 3.75 (dd, J = 10.8, 3.3 Hz, 2H), 1.03 (s, 18H), 1.02 (s, 18H). ¹³C **NMR** (100 MHz, CDCl₃) δ 178.2, 157.5, 147.8, 145.2, 135.6, 135.5, 132.7, 132.6, 130.1, 130.0, 130.0, 128.0, 128.0, 127.7, 123.8, 106.8, 79.5, 61.9, 55.7, 38.8, 27.5, 26.9, 19.3. **HRMS** (ESI) m/z Calcd for [C₆₆H₇₇IN₄O₁₀Si₂, M+H]⁺: 1269.4296, found 1269.4279.



Cat-4 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 1-adamantanecarbonyl chloride (437.8 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.331

g, 0.92 mmol, 92%) as a white solid. **MP:** 130.5-133.2 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.14 (d, *J* = 8.7 Hz, 4H), 7.59-7.50 (m, 12H), 7.48-7.27 (m, 8H), 7.26-7.20 (m, 4H), 6.86 (t, *J* = 8.3 Hz, 1H), 6.20 (d, *J* = 8.3 Hz, 2H), 6.07 (d, *J* = 8.4 Hz, 2H), 5.48 (d, *J* = 6.2 Hz, 2H), 4.56-4.46 (m, 2H), 4.38 (dd, *J* = 10.7, 5.4 Hz, 2H), 3.77 (dd, *J* = 10.7, 3.3 Hz, 2H), 1.98 (s, 6H), 1.75-1.57 (m, 24H), 1.03 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 177.7, 157.5, 147.7, 145.3, 135.6, 135.5, 132.7, 132.7, 130.1, 130.0, 129.9, 127.9, 127.9, 127.6, 123.7, 106.7, 79.5, 79.4, 62.0, 55.4, 40.6, 39.2, 36.4, 28.0, 26.9, 19.3. **HRMS** (ESI) m/z Calcd for [C₇₈H₈₉IN₄O₁₀Si₂, M+Na]⁺: 1447.5054, found 1447.5073.



Cat-5 was prepared using **SI-13** (886 mg, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and pivaloyl chloride (265.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified

by DCM and hexane to precipitate the title compound (970 mg, 0.92 mmol, 92%) as a white solid. **MP:** 67.2-67.8 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.68-7.63 (m, 4H), 7.56-7.51 (m, 4H), 7.46-7.41 (m, 2H), 7.41-7.33 (m, 6H), 7.29-7.23 (m, 4H), 7.18 (t, *J* = 8.3 Hz, 1H), 6.46 (d, *J* = 8.4 Hz, 2H), 6.21 (d, *J* = 8.6 Hz, 2H), 4.67 (p, *J* = 6.3 Hz, 2H), 4.38-4.23 (m, 4H), 3.87 (dd, *J* = 10.4, 3.4 Hz, 2H), 1.39 (d, *J* = 6.4 Hz, 6H), 1.17 (s, 18H), 1.04 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.2, 158.3, 135.6, 135.6, 133.0, 132.7, 130.0, 129.9, 127.9, 127.9, 105.9, 81.1, 74.8, 62.3, 54.6, 38.9, 27.6, 26.9, 19.3, 16.8. **HRMS** (ESI) m/z Calcd for [C₆₆H₇₇IN₄O₁₀Si₂, M+H]⁺: 1055.4281, found 1055.4306



Cat-6 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *p*-toluoyl chloride (339 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.096 g, 0.82 mmol, 82%) as a white solid. **MP:** 112.4-114.5 °C. ¹**H**

NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 8.4 Hz, 4H), 7.51-7.40 (m, 16H), 7.31-7.24 (m, 4H), 7.21-7.12 (m, 12H), 6.71 (t, J = 8.3 Hz, 1H), 6.57 (d, J = 8.5 Hz, 2H), 5.94 (d, J = 8.4 Hz, 2H), 5.47 (d, J = 5.6 Hz, 2H), 4.69-4.59 (m, 2H), 4.34 (dd, J = 10.9, 6.1 Hz, 2H), 3.82 (dd, J = 10.9, 3.4 Hz, 2H), 2.30 (s, 6H), 0.91 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 167.0, 157.2, 147.7, 144.9, 142.5, 135.6, 135.5, 132.8, 132.7, 131.0, 130.0, 130.0, 129.4, 127.9, 127.4, 126.9, 123.9, 106.9, 80.0, 79.6, 61.9, 56.3, 26.9, 21.5, 19.2. HRMS (ESI) m/z Calcd for [C₇₂H₇₃IN₄O₁₀Si₂, M+Na]⁺: 1359.3802, found 1359.3774.



Cat-7 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-(trifluoromethyl)-benzoylchlorid (458.9 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.127 g, 0.78 mmol, 78%) as a white solid. **MP:** 120.3-

121.5 °C. ¹**H** NMR (400 MHz, CDCl₃) δ 8.02 (d, J = 8.7 Hz, 4H), 7.65-7.55 (m, 8H), 7.50-7.40 (m, 12H), 7.33-7.25 (m, 4H), 7.22-7.14 (m, 8H), 6.76 (t, J = 8.3 Hz, 1H), 6.58 (d, J = 8.5 Hz, 2H), 5.97 (d, J = 8.4 Hz, 2H), 5.48 (d, J = 5.5 Hz, 2H), 4.71-4.60 (m, 2H), 4.36 (dd, J = 11.0, 6.2 Hz, 2H), 3.83 (dd, J = 11.0, 3.4 Hz, 2H), 0.93 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 165.9, 157.2, 147.9, 144.6, 137.1, 135.6, 135.6, 133.6 (q, ² $_{J_{C-F}} = 32.7$ Hz), 132.7, 132.7, 130.2, 130.1, 128.0, 128.0, 127.4, 125.8 (q, ³ $_{J_{C-F}} = 3.7$ Hz), 124.0, 123.7 (q, ¹ $_{J_{C-F}} = 272.5$ Hz), 107.1, 80.0, 79.5, 61.8, 56.5, 26.9, 19.3. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.86. HRMS (ESI) m/z Calcd for [C₇₂H₆₇F₆IN₄O₁₀Si₂, M+Na]⁺: 1445.3417, found 1445.3431.



Cat-8 was prepared using **SI-13** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH to precipitate the title compound (1.198 g, 0.86 mmol, 86%) as a white solid. **MP:** 205.0-207.3 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.09 (d, J = 8.8 Hz, 4H), 7.53-7.40 (m, 12H), 7.30-7.24 (m, 4H), 7.18-7.11 (m, 8H), 6.78 (t, J = 8.3 Hz, 1H), 6.73 (s, 4H), 6.02 (dd, J = 8.2, 2.3 Hz, 4H), 5.69 (d, J = 4.9 Hz, 2H), 4.71-4.59 (m, 2H), 4.30 (dd, J = 11.2, 6.8 Hz, 2H), 3.81 (dd, J = 11.1, 3.1 Hz, 2H), 2.22 (s, 6H), 1.88 (s, 12H), 0.94 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 170.7, 157.1, 147.9, 144.7, 138.9, 135.5, 134.2, 134.2, 132.7, 132.5, 130.1, 130.0, 129.9, 128.3, 127.9, 127.7, 124.0, 106.5, 79.5, 79.3, 61.7, 57.0, 26.9, 21.1, 19.2, 18.9. **HRMS** (ESI) m/z Calcd for [C₇₆H₈₁IN₄O₁₀Si₂, M+Na]⁺: 1415.4428, found 1415.4434.



Cat-9 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-nitrobenzoyl chloride (408.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.3 g, 0.93 mmol, 93%) as a white solid. **MP:** 130.5-132.7 °C. ¹H

NMR (400 MHz, CDCl₃) δ 8.16 (d, J = 8.5 Hz,

4H), 8.03 (d, J = 8.4 Hz, 4H), 7.64 (d, J = 8.6 Hz, 4H), 7.50-7.41 (m, 12H), 7.34-7.27 (m, 4H), 7.23-7.15 (m, 8H), 6.77 (t, J = 8.3 Hz, 1H), 6.60 (d, J = 8.5 Hz, 2H), 5.98 (d, J = 8.4 Hz, 2H), 5.49 (d, J = 5.5 Hz, 2H), 4.65 (dtd, J = 9.2, 5.9, 3.4 Hz, 2H), 4.37 (dd, J = 11.0, 6.3 Hz, 2H), 3.84 (dd, J = 11.1, 3.4 Hz, 2H), 0.92 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 157.2, 149.8, 147.9, 144.4, 139.3, 135.6, 135.6, 132.6, 130.2, 130.1, 128.1, 128.1, 128.0, 127.4, 124.0, 123.9, 107.1, 79.9, 79.4, 61.7, 56.6, 26.9, 19.3. HRMS (ESI) m/z Calcd for [C₇₀H₆₇IN₆O₁₄Si₂, M+Na]⁺: 1421.3191, found 1421.3219.



Cat-10 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-methoxybenzoyl chloride (375.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.232 g, 0.90 mmol, 90%) as a white solid. **MP:** 80.1-

81.6 °C. ¹**H** NMR (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.3 Hz, 4H), 7.61 (d, *J* = 8.4 Hz, 4H), 7.58-7.50 (m, 12H), 7.42-7.35 (m, 4H), 7.31-7.24 (m, 8H), 6.93 (d, *J* = 8.3 Hz, 4H), 6.80 (t, *J* = 8.3 Hz, 1H), 6.56 (d, *J* = 8.2 Hz, 2H), 6.02 (d, *J* = 8.3 Hz, 2H), 5.55 (d, *J* = 5.2 Hz, 2H), 4.76-4.66 (m, 2H), 4.42 (dd, *J* = 10.8, 6.0 Hz, 2H), 3.93-3.88 (m, 2H), 3.88 (s, 6H), 1.01 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 166.7, 162.6, 157.3, 147.7, 145.0, 135.7, 135.6, 132.9, 132.8, 130.1, 130.0, 128.8, 128.0, 127.4, 126.1, 124.0, 114.0, 107.0, 80.2, 79.6, 61.9, 56.4, 55.6, 26.9, 19.3. HRMS (ESI) m/z Calcd for [C₇₂H₇₃IN₄O₁₂Si₂, M+Na]⁺: 1421.3191, found 1421.3219.



Cat-11 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and benzoyl chloride (309.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.138 g, 0.87 mmol, 87%) as a white solid. **MP:** 161.3-162.5 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.8 Hz, 4H), 7.56-7.52 (m, 4H), 7.49-7.41 (m, 14H), 7.38-7.33 (m, 4H), 7.32-7.25 (m, 4H), 7.22-7.14 (m, 8H), 6.73 (t, *J* = 8.3 Hz, 1H), 6.55 (d, *J* = 8.5 Hz, 2H), 5.94 (d, *J* = 8.4 Hz, 2H), 5.47 (d, *J* = 5.5 Hz, 2H), 4.68-4.60 (m, 2H), 4.34 (dd, *J* = 10.9, 6.1 Hz, 2H), 3.81 (dd, *J* = 10.9, 3.4 Hz, 2H), 0.92 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 167.2, 157.3, 147.8, 144.9, 135.7, 135.6, 133.9, 132.8, 132.8, 132.0, 130.1, 130.1, 128.8, 128.0, 127.4, 127.0, 124.0, 107.0, 80.0, 79.6, 61.9, 56.4, 26.9, 19.3. **HRMS** (ESI) m/z Calcd for [C₇₀H₆₉IN₄O₁₀Si₂, M+H]⁺: 1309.3670, found 1309.3664.



Cat-12 was prepared using **SI-13** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude

residue was purified by CH₂Cl₂ and hexane to precipitate the title compound (1.138 g, 0.87 mmol, 87%) as a white solid. **MP:** 223.5-224.7 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.67 (d, *J* = 7.2 Hz, 4H), 7.58 (d, *J* = 7.3 Hz, 4H), 7.44 (t, *J* = 7.3 Hz, 2H), 7.36 (t, *J* = 7.4 Hz, 6H), 7.31-7.24 (m, 4H), 7.20 (t, *J* = 8.3 Hz, 1H), 6.85 (s, 4H), 6.47 (d, *J* = 8.4 Hz, 2H), 6.05 (d, *J* = 8.6 Hz, 2H), 4.84 (p, *J* = 6.1 Hz, 2H), 4.56 (m, 2H), 4.32 (dd, *J* = 10.8, 5.6 Hz, 2H), 4.06 (dd, *J* = 10.9, 3.6 Hz, 2H), 2.31 (s, 6H), 2.20 (s, 12H), 1.47 (d, *J* = 6.3 Hz, 6H), 1.06 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 170.6, 157.7, 138.6, 135.7, 135.6, 134.8, 134.2, 133.1, 132.8, 130.0, 129.9, 129.9, 128.4, 127.9, 127.9, 105.7, 74.3, 62.5, 55.6, 27.0, 21.2, 19.3, 19.2, 16.7. **HRMS** (ESI) m/z Calcd for [C₆₆H₇₉IN₂O₆Si₂, M+H]⁺: 1179.4600, found 1179.4610.



Cat-13 was prepared using **SI-13** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-nitrobenzoyl chloride (408.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by DCM and hexane to precipitate the title compound

(1.1 g, 0.93 mmol, 93%) as a white solid. **MP:** 107.4-109.8 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.25 (d, *J* = 8.6 Hz, 4H), 7.78 (d, *J* = 8.8 Hz, 4H), 7.66-7.53 (m, 8H), 7.48-7.32 (m, 8H), 7.30-7.24 (m, 4H), 7.17 (t, *J* = 8.3 Hz, 1H), 6.63-6.53 (m, 2H), 6.46 (d, *J* = 8.5 Hz, 2H), 4.77-4.69 (m, 2H), 4.59-4.49 (m, 2H), 4.38-4.27 (m, 2H), 4.14-4.04 (m, 2H), 1.44 (d, *J* = 6.6 Hz, 6H), 1.03 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 165.2, 158.1, 149.7, 140.0, 135.7, 135.7, 133.1, 132.8, 130.2, 130.1, 128.3, 128.1, 128.0, 123.9, 106.3, 81.2, 75.4, 62.2, 55.7, 27.0, 19.4, 16.9. **HRMS** (ESI) m/z Calcd for [C₆₀H₆₅IN₄O₁₀Si₂, M+Na]⁺: 1207.3176, found 1207.3190.



Cat-14 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *p*-Tolyl isocyanate (292.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.161 g, 0.85 mmol, 85%) as a white solid. **MP:** 181.1-182.3 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 7.99 (d, J = 8.4 Hz, 4H), 7.43 – 7.37 (m, 8H), 7.34 (d, J = 7.4 Hz, 4H), 7.30 – 7.26 (m, 2H), 7.20 – 7.15 (m, 6H), 7.08 – 7.00 (m, 8H), 6.93 (d, 4H), 6.70 (t, J = 8.3 Hz, 1H), 6.52 (s, 2H), 5.92 (d, J = 8.4 Hz, 2H), 5.36 (d, J = 6.4 Hz, 2H), 5.27 (d, J = 8.5 Hz, 2H), 4.39 – 4.31 (m, 2H), 4.22 (dd, J = 10.7, 5.0 Hz, 2H), 3.68 (dd, J = 10.8, 3.2 Hz, 2H), 2.22 (s, 6H), 0.82 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 157.1, 155.7, 147.7, 145.4, 135.5, 135.5, 135.2, 134.9, 132.7, 132.6, 130.3, 130.0, 129.8, 127.9, 127.9, 127.8, 123.8, 123.3, 106.5, 79.3, 79.3, 62.3, 56.6, 26.8, 21.0, 19.2. **HRMS** (ESI) m/z Calcd for [C₇₂H₇₅IN₆O₁₀Si₂, M+H]⁺: 1367.4201, found 1367.4210.



Cat-15 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-(trifluoromethoxy)phenyl isocyanate (446.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH

and water to precipitate the title compound (1.161 g, 0.87 mmol, 87%) as a white solid. **MP:** 136.0-138.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (d, J = 8.8 Hz, 4H), 7.58-7.53 (m, 8H), 7.48 (d, J = 8.9 Hz, 4H), 7.43-7.30 (m, 8H), 7.29-7.23 (m, 4H), 7.20-7.08 (m, 8H), 6.84 (t, J = 8.3 Hz, 1H), 6.53 (s, 2H), 6.05 (d, J = 8.4 Hz, 2H), 5.54 (d, J = 5.4 Hz, 2H), 5.19 (d, J = 8.0 Hz, 2H), 4.46-4.33 (m, 4H), 3.86 (dd, J = 10.6, 3.3 Hz, 2H), 0.99 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 157.1, 154.9, 147.7, 145.3, 145.0, 136.8, 135.6, 135.6, 132.9, 132.9, 130.2, 130.1, 128.0, 128.0, 127.6, 123.9, 122.2, 122.0, 120.5 (d, ¹ $J_{C-F} = 257.2$ Hz), 106.8, 79.9, 79.3, 62.2, 57.1, 26.9,

19.3, 19.3. ¹⁹**F NMR** (376 MHz, CDCl₃) δ -58.09. **HRMS** (ESI) m/z Calcd for $[C_{72}H_{69}F_6IN_6O_{12}Si_2, M+H]^+$: 1529.3353, found 1529.3379.



Cat-16 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *o*-Tolyl isocyanate (292.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.190 g, 0.87 mmol, 87%) as a white solid. **MP:** 137.0-140.4 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.19 (d, J = 8.6 Hz, 4H), 7.59-7.48 (m, 8H), 7.45-7.38 (m, 6H), 7.37-7.29 (m, 8H), 7.29-7.23 (m, 4H), 7.22-7.10 (m, 6H), 6.84 (t, J = 8.3 Hz, 1H), 6.59 (s, 2H), 6.06 (d, J = 8.4 Hz, 2H), 5.46 (d, J = 6.9 Hz, 2H), 5.26 (d, J = 8.6 Hz, 2H), 4.58-4.46 (m, 2H), 4.31 (dd, J = 10.6, 4.6 Hz, 2H), 3.79 (dd, J = 10.7, 3.2 Hz, 2H), 2.18 (s, 6H), 0.94 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 157.0, 156.0, 147.8, 145.5, 135.5, 135.4, 134.3, 132.6, 132.5, 131.5, 130.0, 129.8, 129.8, 127.9, 127.9, 127.8, 127.5, 127.2, 126.8, 123.7, 106.4, 79.3, 79.1, 62.2, 56.4, 26.8, 19.2, 18.0. **HRMS** (ESI) m/z Calcd for [C₇₂H₇₅IN₆O₁₀Si₂, M+H]⁺: 1367.4201, found 1367.4200.



Cat-17 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *m*-Tolyl isocyanate (292.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.152 g, 0.83 mmol, 83%) as a white solid. **MP:** 139.0-142.8 °C.

¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (d, J = 8.4 Hz, 4H), 7.56-7.47 (m, 12H), 7.40-7.35 (m, 2H), 7.35-7.26 (m, 6H), 7.23-7.15 (m, 6H), 7.00 (s, 2H), 6.95 (m, 4H), 6.82 (t, J = 8.3 Hz, 1H), 6.78 (s, 2H), 6.05 (d, J = 8.5 Hz, 2H), 5.53 (d, J = 6.0 Hz, 2H), 5.48 (d, J = 8.4 Hz, 2H), 4.53-4.45 (m, 2H), 4.35 (dd, J = 10.8, 5.4 Hz, 2H), 3.84 (dd, J = 10.9, 3.3 Hz, 2H), 2.30 (s, 6H), 0.96 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 157.1, 155.5, 147.6, 145.3, 139.6, 137.7, 135.5, 135.5, 132.8, 132.7, 130.0, 129.9, 129.4, 127.9, 127.9, 127.7, 125.7, 123.8, 123.0, 119.3, 106.5, 79.5, 79.2, 62.2, 56.7, 26.8, 21.5, 19.2. **HRMS** (ESI) m/z Calcd for [C₇₂H₇₅IN₆O₁₀Si₂, M+Na]⁺: 1389.4020, found 1389.4021.



Cat-18 was prepared using 11 (1.1 g, 1.0mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3mmol, 2.3 equiv.)and(Trifluoromethyl)benzene-1-

sulfonylchloride (539 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by

MeOH to precipitate the title compound (1.322 g, 0.86 mmol, 86%) as a white solid. **MP:** 116.3-119.7 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.3 Hz, 4H), 7.77 (d, *J* = 8.1 Hz, 4H), 7.51 (d, *J* = 8.2 Hz, 4H), 7.46-7.37 (m, 14H), 7.33-7.23 (m, 6H), 7.16 (t, *J* = 7.5 Hz, 4H), 6.81 (t, *J* = 8.3 Hz, 1H), 5.99 (d, *J* = 8.4 Hz, 2H), 5.44 (d, *J* = 6.2 Hz, 2H), 5.28 (d, *J* = 8.7 Hz, 2H), 4.24 (dd, *J* = 10.9, 4.7 Hz, 2H), 3.81-3.76 (m, 2H), 3.59 (dd, *J* = 11.0, 3.4 Hz, 2H), 0.93 (s, 18H). ¹³C **NMR** (100 MHz, CDCl₃) δ 156.7, 148.0, 144.1, 143.9, 135.5, 134.5 (q, ²*JC*-*F* = 32.7 Hz), 132.2, 132.2, 130.3, 130.1, 130.1, 128.0, 128.0, 127.8, 127.3, 126.3 (q, ³*JC*-*F* = 4.0 Hz), 124.0, 123.1 (q, ¹*J C*-*F* = 273.2 Hz), 106.7, 79.2, 79.1, 61.7, 60.6, 26.9, 19.2. ¹⁹F **NMR** (376 MHz, CDCl₃) δ -66.13. **HRMS** (ESI) m/z Calcd for [C₇₀H₆₇F₆IN₄O₁₂S₂Si₂, M+Na]⁺: 1539.2577, found 1539.2573.



Cat-19 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-tertbutylbenzenesulfonyl chloride (513 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH to precipitate the title compound (1.223 g, 0.82 mmol, 82%) as a white solid. **MP:** 128.3-130.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.09 (d, *J* = 8.6 Hz, 4H), 7.57 (d, *J* = 8.5 Hz, 4H), 7.46 – 7.35 (m, 14H), 7.30 – 7.24 (m, 10H), 7.17 – 7.10

(m, 4H), 6.80 (t, J = 8.3 Hz, 1H), 6.01 (d, J = 8.4 Hz, 2H), 5.46 (d, J = 6.5 Hz, 2H), 5.24 (d, J = 8.5 Hz, 2H), 4.26 (dd, J = 10.7, 4.4 Hz, 2H), 3.76 – 3.68 (m, 2H), 3.65 (dd, J = 10.8, 3.4 Hz, 2H), 1.25 (s, 18H), 0.94 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 156.8, 156.7, 147.9, 144.6, 137.1, 135.5, 135.4, 132.4, 130.1, 129.9, 127.9, 127.9, 126.8, 126.1, 123.9, 106.6, 79.3, 78.8, 61.8, 60.2, 35.1, 31.1, 26.9, 19.3. **HRMS** (ESI) m/z Calcd for [C₇₆H₈₅IN₄O₁₂S₂Si₂, M+Na]⁺: 1515.4081, found 1515.4094.



Cat-20 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-tertbutylbenzenesulfonyl chloride (563 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH to precipitate the title compound (1.382 g, 0.9 mmol, 90%) as a white solid. **MP:** 116.2-118.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.8 Hz, 4H), 7.51-7.34 (m, 22H), 7.34-7.26 (m, 6H), 7.14 (t, *J* = 7.6 Hz, 4H), 6.82 (t, *J* = 8.4 Hz, 1H), 6.00 (d, *J* = 8.5 Hz, 2H), 5.41 (d, *J* = 6.6 Hz, 2H), 5.24 (d, *J* = 8.8 Hz, 2H), 4.24 (dd, *J* = 10.8, 4.3 Hz, 2H), 3.80-3.70 (m, 1H), 3.61 (dd, *J* = 10.8, 3.4 Hz, 2H), 0.95 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 156.6, 147.9, 144.3, 139.3, 135.5, 135.4, 132.4, 132.2, 130.2, 130.1, 130.0, 128.3, 128.0, 127.9, 127.9, 124.0, 106.6, 79.3, 78.7, 61.8, 60.4, 26.9, 19.2. **HRMS** (ESI) m/z Calcd for [C₆₈H₆₇Br₂IN₄O₁₂S₂Si₂, M+Na]⁺: 1559.1039, found 1559.1039.



Cat-21 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and Tosyl chloride (419.4 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to

precipitate the title compound (1.324 g, 0.94 mmol, 94%) as a white solid. **MP:** 116.0-119.6 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.86 (d, *J* = 8.5 Hz, 4H), 7.40-7.17 (m, 18H), 7.15-7.05 (m, 6H), 7.00-6.90 (m, 4H), 6.86 (d, *J* = 8.1 Hz, 4H), 6.64 (t, *J* = 8.3 Hz, 1H), 5.88 (d, J = 8.5 Hz, 2H), 5.39-5.21 (m, 4H), 4.16 (dd, J = 10.6, 3.6 Hz, 2H), 3.73-3.51 (m, 4H), 2.12 (s, 6H), 0.80 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 156.5, 147.6, 144.7, 143.5, 137.2, 135.4, 135.3, 132.3, 129.9, 129.7, 129.5, 127.9, 127.8, 127.7, 126.7, 123.6, 106.4, 79.2, 78.1, 62.1, 60.1, 26.8, 21.3, 19.1. **HRMS** (ESI) m/z Calcd for [C₇₀H₇₃IN₄O₁₂S₂Si₂, M+H]⁺: 1409.3322, found 1409.3314.



Cat-22 was prepared using **SI-13'** (886.3 mg, 1.0 mmol, 1.0 equiv.) starting from *L*-threonine, Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and

mesitylcarbonylchloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was recrystallized by CH_2Cl_2 and hexane to yield the title compound as a white solid (1.013 g, 0.86 mmol, 86%).



Cat-23 was prepared using **SI-13'** (886.3 mg, 1.0 mmol, 1.0 equiv.) starting from *L*-threonine, Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and pivaloyl

chloride (265.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was recrystallized by CH_2Cl_2 and hexane to yield the title compound as a white solid (0.78 g, 0.74 mmol, 74%).



Cat-24 was prepared using **11'** (1.1 g, 1.0 mmol, 1.0 equiv.) starting from (1R,2R)-ANP, Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol,

2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound as a white solid (1.198 g, 0.86 mmol, 86%).


Cat-25 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-methoxybenzoyl chloride (375.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.1 g, 0.93 mmol, 93%) as a white solid. **MP:** 220.1-221.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ

8.18 (d, J = 8.8 Hz, 4H), 7.78 (d, J = 8.9 Hz, 4H), 7.63 (d, J = 8.6 Hz, 4H), 7.08 (d, J = 7.9 Hz, 2H), 6.95 (d, J = 8.8 Hz, 4H), 6.85-6.81 (t, J = 8.3 Hz, 1H), 6.79 (s, 4H), 6.04 (d, J = 8.4 Hz, 2H), 5.72 (d, J = 3.6 Hz, 2H), 5.40-5.28 (m, 2H), 4.95-4.82 (m, 2H), 4.32 (dd, J = 11.9, 3.6 Hz, 2H), 3.87 (s, 6H), 2.25 (s, 6H), 2.16 (s, 12H). ¹³C **NMR** (100 MHz, CDCl₃) δ 170.7, 166.8, 162.8, 157.4, 147.9, 144.1, 140.0, 135.3, 130.3, 129.9, 129.0, 128.6, 127.1, 125.4, 124.3, 114.0, 107.4, 81.2, 79.4, 61.8, 55.6, 55.6, 21.2, 19.9. **HRMS** (ESI) m/z Calcd for [C₆₀H₅₇IN₄O₁₄, M+Na]⁺: 1207.2808, found 1207.2811.



Cat-26 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trichlorobenzoyl chloride (534.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.234 g, 0.93 mmol, 93%) as a white

solid. **MP:** 170.4-173.9 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.8 Hz, 4H), 7.64 (d, *J* = 8.8 Hz, 4H), 7.23 (s, 4H), 6.91 (t, *J* = 8.3 Hz, 1H), 6.79 (s, 6H), 6.15 (d, *J* = 8.4 Hz, 2H), 5.81 (d, *J* = 4.3 Hz, 2H), 5.07 (dd, *J* = 11.7, 7.3 Hz, 2H), 5.00-4.90 (m, 2H), 4.58 (dd, *J* = 11.8, 4.0 Hz, 2H), 2.26 (s, 6H), 2.17 (s, 12H). ¹³**C NMR** (100 MHz, CDCl₃) δ 169.7, 164.0, 156.9, 147.9, 143.8, 140.1, 136.4, 135.6, 133.4, 132.8, 129.4, 128.7, 128.2, 127.5, 124.2, 107.1, 79.9, 61.8, 54.9, 21.2, 20.2. **HRMS** (ESI) m/z Calcd for [C₅₈H₄₇Cl₆IN₄O₁₂, M+Na]⁺: 1351.0259, found 1351.0238.



Cat-27 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 3,5-bis(trifluoromethyl)benzoyl chloride (609.4 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH and water to precipitate the title compound (1.234 g, 0.94

mmol, 94%) as a white solid. **MP:** 140.0-142.7 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.28 (d, J = 1.6 Hz, 4H), 8.19 (d, J = 8.8 Hz, 4H), 8.05 (s, 2H), 7.67 (d, J = 8.9 Hz, 4H), 7.56 (d, J = 8.0 Hz, 2H), 6.90 (t, J = 8.3 Hz, 1H), 6.81 (s, 4H), 6.12 (d, J = 8.5Hz, 2H), 5.76 (d, J = 4.0 Hz, 2H), 5.28 (dd, J = 11.9, 8.6 Hz, 2H), 5.03-4.94 (m, 2H), 4.45 (dd, J = 12.0, 3.5 Hz, 2H), 2.25 (s, 6H), 2.18 (s, 12H). ¹³C **NMR** (100 MHz, CDCl₃) δ 170.6, 164.5, 157.3, 148.1, 143.7, 140.3, 135.5, 135.5, 132.43 (q, ² $_{JC-F} =$ 34.2 Hz), 130.5, 129.5, 128.8, 127.6, 127.6, 127.2, 125.7 (q, ³ $_{JC-F} = 2.2$ Hz), 124.4, 122.9 (q, ¹ $_{JC-F} = 272.5$ Hz), 107.5, 80.8, 79.0, 61.9, 55.7, 21.1, 20.0. ¹⁹F **NMR** (376 MHz, CDCl₃) δ -62.83. **HRMS** (ESI) m/z Calcd for [C₆₂H₄₉F₁₂IN₄O₁₂, M+Na]⁺: 1419.2092, found 1419.2098.



Cat-28 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 3,5-dichlorobenzoyl chloride (459.8 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH and water to precipitate the title compound (1.171 g, 0.93 mmol, 93%) as a

white solid. **MP:** 180.0-182.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.8 Hz, 4H), 7.65 (d, *J* = 8.6 Hz, 8H), 7.53 (t, *J* = 1.9 Hz, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 6.87 (t, *J* = 8.3 Hz, 1H), 6.81 (s, 4H), 6.08 (d, *J* = 8.5 Hz, 2H), 5.69 (d, *J* = 3.9 Hz, 2H), 5.25 (dd, *J* = 11.9, 8.8 Hz, 2H), 4.94-4.83 (m, 2H), 4.38 (dd, *J* = 11.9, 3.5 Hz, 2H),

2.26 (s, 6H), 2.17 (s, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 164.8, 157.4, 148.1, 143.7, 140.2, 136.2, 135.8, 135.5, 132.2, 130.5, 129.7, 128.8, 127.2, 125.8, 124.4, 107.5, 80.9, 79.3, 61.8, 55.6, 21.2, 20.1. **HRMS** (ESI) m/z Calcd for [C₅₈H₄₉Cl₄IN₄O₁₂, M+H]⁺: 1261.1219, found 1261.1220.



Cat-29 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-triBromobenzoyl chloride (600.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.271 g, 0.8 mmol, 80%) as a white solid. **MP:** 171.2-175.9 °C. ¹H NMR (400

MHz, CDCl₃) δ 8.21 (dd, J = 9.0, 2.3 Hz, 4H), 7.67-7.59 (m, 8H), 6.88 (t, J = 8.3 Hz, 1H), 6.80 (s, 4H), 6.57 (d, J = 8.0 Hz, 2H), 6.10 (d, J = 8.4 Hz, 2H), 5.83 (d, J = 3.8 Hz, 2H), 5.03-4.88 (m, 4H), 4.57 (dd, J = 11.3, 3.6 Hz, 2H), 2.27 (s, 6H), 2.20 (s, 12H). ¹³**C NMR** (100 MHz, CDCl₃) δ 169.7, 165.9, 157.0, 148.1, 143.7, 140.3, 137.7, 135.8, 134.5, 130.3, 129.5, 128.8, 127.4, 124.5, 124.4, 120.8, 107.3, 80.2, 80.1, 61.5, 54.8, 21.3, 20.5. **HRMS** (ESI) m/z Calcd for [C₅₈H₄₇Br₆IN₄O₁₂, M+Na]⁺: 1614.7228, found 1614.7188.



Cat-30 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and BzCl (310.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to

precipitate the title compound (0.9 g, 0.80 mmol, 80%) as a white solid. **MP:** 160.4-163.1 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.19 (d, J = 8.8 Hz, 4H), 7.82 (d, J = 7.5 Hz, 4H), 7.64 (d, J = 8.8 Hz, 4H), 7.57 (t, J = 7.4 Hz, 2H), 7.48 (t, J = 7.7 Hz, 4H), 7.16 (d, J = 8.0 Hz, 2H), 6.83 (t, J = 8.3 Hz, 1H), 6.79 (s, 4H), 6.04 (d, J = 8.4 Hz, 2H), 5.72 (d, J = 3.8 Hz, 2H), 5.34 (dd, J = 11.9, 8.9 Hz, 2H), 4.95-4.86 (m, 2H), 4.34 (dd, J = 11.9, 3.6 Hz, 2H), 2.25 (s, 6H), 2.16 (s, 12H). ¹³**C NMR** (100 MHz, CDCl₃) δ 170.7, 167.3, 157.4, 148.0, 144.0, 140.1, 135.4, 133.2, 132.4, 130.4, 129.9, 129.0, 128.7, 127.2, 127.1, 124.4, 107.4, 81.1, 79.4, 61.8, 55.6, 21.2, 20.0. **HRMS** (ESI) m/z Calcd for [C₅₈H₅₃IN₄O₁₂, M+Na]⁺: 1147.2597, found 1147.2590.



Cat-31 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title

compound (1.0 g, 0.83 mmol, 83%) as a white solid. **MP:** 164.0-167.0 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.5 Hz, 4H), 7.66 (d, *J* = 8.5 Hz, 4H), 6.94 (t, *J* = 8.4 Hz, 1H), 6.80 (d, *J* = 11.4 Hz, 8H), 6.45 (d, *J* = 8.6 Hz, 2H), 6.19 (d, *J* = 8.6 Hz, 2H), 5.78 (d, *J* = 4.9 Hz, 2H), 5.08-5.03 (m, 1H), 4.95 (dd, *J* = 11.7, 7.2 Hz, 2H), 4.63 (dd, *J* = 11.7, 3.2 Hz, 2H), 2.27 (s, 12H), 2.20 (s, 12H), 1.97 (s, 12H). ¹³**C NMR** (100 MHz, CDCl₃) δ 170.5, 169.4, 156.9, 147.8, 143.9, 139.9, 139.0, 135.3, 133.9, 133.7, 130.1, 129.6, 128.5, 128.3, 127.5, 124.0, 106.8, 79.9, 79.5, 62.2, 53.8, 21.1, 21.0, 20.0, 18.7. **HRMS** (ESI) m/z Calcd for [C₆₄H₆₅IN₄O₁₂, M+H]⁺: 1209.3716, found 1209.3719.



Cat-32 was prepared using **SI-4-2** (0.708 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and acetyl chloride (173.8 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (0.665 g, 0.84 mmol, 84%) as a white

solid. **MP:** 161.3-164.1 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.6 Hz, 4H), 7.57 (d, *J* = 8.6 Hz, 4H), 6.87 (t, *J* = 8.4 Hz, 1H), 6.30 (d, *J* = 8.0 Hz, 2H), 6.05 (d, *J* = 8.5 Hz, 2H), 5.54 (d, *J* = 3.3 Hz, 2H), 4.72-4.53 (m, 4H), 4.21-4.09 (m, 2H), 1.99 (s, 12H). ¹³**C NMR** (100 MHz, CDCl₃) δ 171.2, 170.4, 157.1, 147.9, 144.0, 130.3, 127.2, 124.3, 107.3, 80.8, 79.2, 61.6, 54.0, 23.5, 20.9. **HRMS** (ESI) m/z Calcd for [C₃₂H₃₃IN₄O₁₂, M+H]⁺: 793.1212, found 793.1217.



Cat-33 was prepared using **SI-4-2** (0.708 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (0.920 g, 0.92 mmol,

92%) as a white solid. **MP:** 298.5-301.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.8 Hz, 4H), 7.64 (d, *J* = 8.8 Hz, 4H), 6.93 (t, *J* = 8.3 Hz, 1H), 6.83 (s, 4H), 6.35 (d, *J* = 8.3 Hz, 2H), 6.14 (d, *J* = 8.5 Hz, 2H), 5.78 (d, *J* = 3.8 Hz, 2H), 4.92-4.83 (m, 2H), 4.68 (dd, *J* = 11.9, 8.9 Hz, 2H), 4.24 (dd, *J* = 11.8, 3.6 Hz, 2H), 2.29 (s, 6H), 2.06 (s, 12H), 2.01 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 170.9, 157.1, 148.1, 143.7, 139.2, 134.1, 133.9, 130.5, 128.4, 127.4, 124.3, 106.9, 80.6, 79.4, 61.4, 54.2, 21.2, 20.8, 18.9. **HRMS** (ESI) m/z Calcd for [C₄₈H₄₉IN₄O₁₂, M+Na]⁺: 1023.2284, found 1043.2294.



Cat-34 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-nitrobenzoyl chloride (408.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.130 g, 0.93 mmol, 93%) as a white solid. **MP:** 168.0-171.5 °C. ¹H **NMR** (400 MHz, CDCl₃) δ 8.30-

8.24 (m, 4H), 8.20 (d, J = 8.9 Hz, 4H), 7.97 (d, J = 8.8 Hz, 4H), 7.65 (d, J = 8.8 Hz, 4H), 7.43 (dd, J = 8.0, 3.6 Hz, 2H), 6.88 (t, J = 8.3 Hz, 1H), 6.79 (s, 4H), 6.08 (dd, J = 8.4, 1.9 Hz, 2H), 5.73 (d, J = 3.9 Hz, 2H), 5.40 (dd, J = 12.0, 9.1 Hz, 2H), 4.95-4.86 (m, 1H), 4.41-4.33 (m, 2H), 2.24 (s, 6H), 2.14 (s, 12H).¹³C NMR (100 MHz, CDCl₃) δ 171.0, 165.2, 157.3, 150.0, 148.1, 143.6, 140.3, 138.6, 135.3, 130.5, 129.5, 128.8, 128.4, 127.1, 124.5, 124.1, 107.6, 81.0, 79.4, 61.8, 56.0, 21.2, 20.0. HRMS (ESI) m/z Calcd for [C₅₈H₄₇Br₆IN₄O₁₂, M+H]⁺: 1209.3716, found 1209.3719.



Cat-35 was prepared using **SI-15-2** (0.974 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH and water to precipitate the title compound (1.126 g, 0.89 mmol, 89%) as a white solid. **MP:** 134.0-137.3 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.8 Hz, 4H), 7.67 (d, *J* = 8.8 Hz, 4H), 6.79 (d, *J* = 16.0 Hz, 10H), 6.22 (d, *J* = 8.6 Hz, 2H), 5.81 (d, *J* = 5.1 Hz, 2H), 5.06 (m, 2H), 4.94 (dd, *J* = 11.7, 6.6 Hz, 2H), 4.57 (dd, *J* = 11.8, 3.9 Hz, 2H), 3.73 (s, 3H), 2.26 (s, 6H), 2.26 (s, 6H), 2.17 (s, 12H), 1.94 (s, 12H). ¹³**C NMR** (100 MHz, CDCl₃) δ 170.6, 169.6, 165.2, 157.0, 148.2, 143.4, 140.2, 139.3, 135.4, 134.1, 133.7, 132.4, 129.7, 128.7, 128.5, 127.7, 124.4, 107.3, 86.1, 79.9, 62.3, 53.8, 52.8, 21.2, 21.2, 20.1, 18.9. **HRMS** (ESI) m/z Calcd for [C₆₆H₆₇IN₄O₁₄, M+Na]⁺: 1289.3591, found 1289.3595.



Cat-36 was prepared using **SI-15-1** (0.930 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH and water to precipitate the title compound (1.038 g, 0.85 mmol, 85%) as a white solid. **MP:** 147.3-149.7 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.9 Hz, 4H), 7.66 (d, *J* = 8.8 Hz, 4H), 6.79 (d, *J* = 4.6 Hz, 8H), 6.29 (d, *J* = 8.4 Hz, 2H), 5.96 (s, 2H), 5.78 (d, *J* = 4.4 Hz, 2H), 4.98 (m, 2H), 4.89 (dd, *J* = 11.6, 7.5 Hz, 2H), 4.55 (dd, *J* = 11.6, 4.0 Hz, 2H), 2.28 (s, 6H), 2.26 (s, 6H), 2.18 (s, 12H), 2.00 (s, 3H), 1.97 (s, 12H). ¹³**C NMR** (100 MHz, CDCl₃) δ 170.7, 169.6, 156.8, 148.0, 144.1, 141.2, 140.1, 139.2, 135.5, 134.2, 133.8, 129.7, 128.6, 128.5, 128.5, 127.5, 124.3, 107.9, 79.9, 75.6, 62.1, 54.2, 21.9, 21.2, 21.2, 20.2, 18.9. **HRMS** (ESI) m/z Calcd for [C₆₅H₆₇IN₄O₁₂, M+Na]⁺: 1245.3692, found 1245.3704.



Cat-37 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.411 g, 0.92 mmol, 92%) as a white solid. **MP:** 159.3-162.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.8 Hz, 4H), 7.53 (d, *J* = 8.8 Hz, 4H),

7.38-7.29 (m, 16H), 7.19 (dd, J = 5.1, 1.9 Hz, 18H), 6.86 (t, J = 8.3 Hz, 1H), 6.11 (t, J = 8.6 Hz, 4H), 5.76 (d, J = 4.6 Hz, 2H), 4.86-4.76 (m, 2H), 3.84 (dd, J = 10.4, 6.9 Hz, 2H), 3.48 (dd, J = 10.4, 3.5 Hz, 2H). ¹³**C NMR** (100 MHz, CDCl₃) δ 163.9, 157.0, 147.9, 144.3, 143.4, 136.3, 133.9, 133.0, 130.2, 128.7, 128.3, 128.0, 127.7, 127.3, 124.1, 106.8, 87.4, 80.1, 79.8, 60.9, 55.8. **HRMS** (ESI) m/z Calcd for [C₇₆H₅₇Cl₆IN₄O₁₀, M+Na]⁺: 1543.0986, found 1543.0985.



Cat-38 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.462 g, 0.82 mmol, 82%) as a white solid. **MP:** 187.2-189.4 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.14 (d, *J* = 8.5 Hz, 4H), 7.66 (s, 4H), 7.52 (d, *J* =

8.8 Hz, 4H), 7.38-7.31 (m, 12H), 7.24-7.17 (m, 18H), 6.84 (t, J = 8.3 Hz, 1H), 6.18-6.02 (m, 3H), 5.82 (d, J = 3.8 Hz, 2H), 4.81-4.71 (m, 2H), 3.89-3.80 (m, 2H), 3.53 (dd, J = 10.4, 3.7 Hz, 2H). ¹³**C NMR** (100 MHz, CDCl₃) δ 165.9, 157.0, 147.8, 144.2, 143.4, 138.1, 134.3, 130.1, 128.7, 128.0, 127.5, 127.3, 124.2, 124.1, 120.9, 106.8, 87.4, 80.3, 79.8, 60.7, 56.2. **HRMS** (ESI) m/z Calcd for [C₇₆H₅₅Br₆IN₄O₁₀, M+Na]⁺: 1806.7955, found 1806.7957.



Cat-39 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.462 g, 0.82 mmol, 82%) as a white solid. **MP:** 185.1-

187.3 °C. ¹**H** NMR (400 MHz, CDCl₃) δ 8.07 (d, *J* = 8.5 Hz, 4H), 7.42 (dd, *J* = 16.3, 8.3 Hz, 8H), 7.31-7.24 (m, 12H), 7.17-6.98 (m, 20H), 6.73 (t, *J* = 8.3 Hz, 1H), 6.01 (dd, *J* = 24.5, 8.2 Hz, 4H), 5.77 (d, *J* = 3.9 Hz, 2H), 4.77-4.65 (m, 2H), 3.79-3.71 (m, 2H), 3.46 (dd, *J* = 10.5, 3.9 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 166.6, 156.9, 147.7, 144.4, 143.4, 139.1, 131.8, 131.7, 130.0, 128.7, 127.9, 127.4, 127.2, 124.0, 120.4, 106.8, 87.3, 80.4, 79.8, 60.7, 56.1. **HRMS** (ESI) m/z Calcd for [C₇₆H₅₇Br₄IN₄O₁₀, M+Na]⁺: 1650.9745, found 1650.9754.



Cat-40 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.148 g, 0.82 mmol, 82%) as a white solid. **MP**:

192.0-194.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, *J* = 8.8 Hz, 4H), 7.51 (d, *J* = 8.8 Hz, 4H), 7.29-7.22 (m, 12H), 7.18-7.01 (m, 18H), 6.82 (t, *J* = 8.3 Hz, 1H), 6.73 (s, 4H), 6.09 (d, *J* = 8.5 Hz, 2H), 6.01 (d, *J* = 8.4 Hz, 2H), 5.75 (d, *J* = 4.9 Hz, 2H), 4.86-4.80 (m, 2H), 3.76 (dd, *J* = 10.2, 6.8 Hz, 2H), 3.41 (dd, *J* = 10.2, 3.4 Hz, 2H), 2.21 (s, 6H), 1.88 (s, 12H). ¹³C NMR (100 MHz, CDCl₃) δ 170.5, 156.9, 147.8, 144.6, 143.3, 138.9, 134.2, 134.1, 130.1, 128.5, 128.3, 127.9, 127.7, 127.2, 123.9, 106.4, 87.2, 79.7, 79.7, 61.3, 55.3, 21.1, 18.9. **HRMS** (ESI) m/z Calcd for [C₈₂H₇₃IN₄O₁₀, M+Na]⁺: 1423.4264, found 1423.4256.



Cat-41 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH₃I (156 uL, 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-8** (1.39 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel eluting with petroleum ether/ethyl acetate (5/1 to

2/1) to get **cat-41** (1.20 g, 83% yield) as a white solid. **MP:** 222.0- 125.4°C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.6 Hz, 4H), 7.58 (d, *J* = 7.0 Hz, 4H), 7.48 (dd, *J* = 12.7, 7.9 Hz, 8H), 7.41 (t, *J* = 7.4 Hz, 2H), 7.37-7.29 (m, 6H), 7.22 (t, *J* = 7.5 Hz, 4H),

6.86 (s, 2H), 6.82 (t, J = 8.4 Hz, 1H), 6.74 (s, 2H), 6.06 (d, J = 8.4 Hz, 2H), 5.90 (d, J = 4.1 Hz, 2H), 5.15-4.97 (m, 2H), 4.70-4.54 (m, 2H), 3.80 (dd, J = 11.8, 3.3 Hz, 2H), 3.09 (s, 6H), 2.27 (s, 6H), 2.20 (s, 6H), 1.69 (s, 6H), 0.99 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 173.0, 156.9, 147.7, 144.7, 138.3, 135.6, 135.5, 133.9, 133.3, 133.2, 132.9, 132.4, 130.2, 129.9, 128.4, 128.3, 127.9, 127.8, 127.4, 124.0, 106.1, 80.0, 78.4, 60.9, 59.5, 33.4, 26.8, 21.2, 19.1, 19.0, 18.3. **HRMS** (ESI) m/z Calcd for [C₇₈H₈₅IN₄O₁₀Si₂, M+Na]⁺: 1443.4741, found 1443.4813.



Cat-43 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH₃I (156 uL, 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-9** (1.42 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel eluting with petroleum ether/ethyl acetate (5/1 to

2/1) to get **Cat-43** [1.22 g, 86% yield. (The atropisomer ratio of **Cat-43** = 4:1 was detected by ¹H NMR in CDCl₃)] as a white solid. **MP:** 164.4- 167.3°C. ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 8.6 Hz, 4H), 8.10 (d, *J* = 8.5 Hz, 4H), 7.66–7.54 (m, 8H), 7.51–7.38 (m, 16H), 7.30 (t, *J* = 7.4 Hz, 4H), 6.80 (t, *J* = 8.4 Hz, 1H), 5.98 (d, *J* = 8.4 Hz, 2H), 5.74 (d, *J* = 5.0 Hz, 2H), 4.84–4.58 (m, 4H), 4.04 (d, *J* = 8.9 Hz, 2H), 3.08 (s, 6H), 1.06 (s, 18H). ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 156.6, 148.5, 147.9, 144.7, 142.4, 135.7, 135.6, 133.0, 132.5, 130.1, 128.0, 128.0, 127.9, 127.2, 124.1, 106.6, 79.7, 78.7, 64.8, 59.3, 36.7, 26.9, 19.3. HRMS (ESI) m/z Calcd for [C₇₂H₇₁IN₆O₁₄Si₂, M+H]⁺: 1449.3504, found 1449.3537.



Supplementary Figure 2. Variable temperature NMR experiments of atropisomers Cat-43 in DMSO- d^6



Cat-45 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH₃I (156 uL, 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-3** (1.27 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel

eluting with petroleum ether/ethyl acetate (10/1 to 3/1) to get **Cat-43** (583 mg, 45% yield) as a white solid. **MP:** 116.0-116.9 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.05 (d, *J* = 8.4 Hz, 4H), 7.74 – 7.22 (m, 24H), 6.71 (t, *J* = 8.3 Hz, 1H), 5.92 (d, *J* = 8.5 Hz, 2H), 5.66 (br s, 2H), 4.77 (br s, 2H), 4.57 (t, *J* = 10.6 Hz, 2H), 3.90 (br s, 2H), 3.26 (br s, 6H), 1.25 (s, 18H), 1.01 (s, 18H). ¹³**C NMR** (100 MHz, CDCl₃) δ 178.7, 156.7, 147.5, 145.4, 135.5, 135.5, 133.1, 132.8, 129.8, 129.7, 129.6, 127.8, 127.2, 123.6, 106.2, 80.0, 78.6, 61.9, 59.2, 39.1, 28.0, 26.7, 19.1. **HRMS** (ESI) m/z Calcd for [C₆₈H₈₁IN₄O₁₀Si₂, M+K]⁺: 1335.4167, found 1335.4230.



Cat-47 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH₃I (156 uL, 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-38** (1.78 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel eluting with petroleum ether/ethyl acetate

(5/1 to 2/1) to get **Cat-47** (1.59 g, 86% yield) as a white solid. ¹**H NMR** (400 MHz, CDCl₃) δ 8.15 (d, J = 8.8 Hz, 4H), 7.74 (d, J = 1.9 Hz, 2H), 7.62 (d, J = 1.9 Hz, 2H), 7.46 (d, J = 8.8 Hz, 4H), 7.34 (dd, J = 6.8, 3.1 Hz, 12H), 7.25-7.16 (m, 18H), 6.75 (t, J = 8.3 Hz, 1H), 5.95 (d, J = 8.5 Hz, 2H), 5.91 (s, 2H), 5.20-5.06 (m, 2H), 3.94 (t, J = 10.5 Hz, 2H), 3.51 (dd, J = 11.0, 3.5 Hz, 2H), 2.91 (s, 6H). ¹³**C NMR** (100 MHz, CDCl₃) δ 168.0, 156.6, 147.7, 144.4, 143.4, 138.2, 134.6, 134.2, 130.1, 128.6, 128.0, 127.3, 127.1, 124.1, 123.6, 120.6, 120.4, 106.1, 87.3, 80.3, 78.5, 60.1, 57.7, 33.1. **HRMS** (ESI) m/z Calcd for [C_{78H59}Br₆IN₄O₁₀, M+Na]⁺: 1834.8268, found 1834.8277.



Cat-48 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by DCM and hexane to precipitate the title compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (s, 4H), 7.41 (d, *J* = 6.8 Hz, 12H), 7.25 – 7.13 (m, 19H), 6.44 (d, *J* =

8.4 Hz, 2H), 5.98 (d, J = 8.6 Hz, 2H), 4.94 – 4.81 (m, 2H), 4.64 – 4.49 (m, 2H), 3.82 (dd, J = 10.1, 6.3 Hz, 2H), 3.62 (dd, J = 10.0, 3.4 Hz, 2H), 1.44 (d, J = 6.4 Hz, 6H). ¹³**C NMR** (100 MHz, CDCl₃) δ 165.7, 157.7, 143.7, 138.6, 134.3, 129.9, 128.9, 128.0, 127.2, 123.8, 121.1, 105.9, 87.1, 82.1, 74.9, 61.5, 54.8, 16.9. **HRMS** (ESI) m/z Calcd for [C₆₆H₇₇Br₆IN₂O₆, M+Na]⁺: 1592.7941, found 1592.7988.



Cat-49 were prepared according to the literature^[8]. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (s, 4H), 7.21 (t, *J* = 8.3 Hz, 1H),

6.54 (d, J = 8.3 Hz, 2H), 6.36 (t, J = 6.3 Hz, 2H), 4.70 (td, J = 6.9, 3.3 Hz, 2H), 3.94 (ddd, J = 14.0, 7.1, 3.3 Hz, 2H), 3.63–3.48 (m, 2H), 1.44 (d, J = 6.3 Hz, 6H). ¹³C **NMR** (100 MHz, CDCl₃) δ 166.0, 157.7, 138.7, 134.4, 130.3, 123.9, 121.0, 107.6, 82.9, 75.2, 44.9, 17.7. **HRMS** (ESI) m/z Calcd for [C₂₆H₂₁Br₆IN₂O₄, M+Na]⁺: 1048.5538, found 1048.5578.



5. General procedure of recycle experiments in oxidative dearomatization

Supplementary Figure 3. Catalyst recovery and recycle experiments in oxidative dearomatization.

General procedure: To a Schlenk tube containing **Cat-8** (417.2 mg, 0.3 mmol, 10 mol%), ^{*m*}CPBA (732.7 mg, 3.6 mmol, 1.2 equiv.) and EtOH (0.873 ml, 5 equiv.) were added CH₂Cl₂ (10 mL) and **12a** (648 mg, 3 mmol, 1.0 equiv.). At the end of each reaction of the cycle, the reaction mixture was quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was then extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated in vacuo, the residue was subsequently dissolved by 30 mL of MeOH, H₂O (10 mL) was finally added to precipitate the catalyst which could enter the next cycle. The filtrate was concentrated in vacuo to get the crude product which could be further recrystallized by the mixture (10 mL, 1:300 volume ratio) of ethyl acetate and petroleum ether. After ten catalytic reactions, 320 mg of catalyst was obtained with a total recovery of 76.4%.

yield of 13a	recovery yield of Cat-8	<i>ee</i> of 13a	
87% (559 mg)	96% (402 mg)	97%	
85% (545 mg)	97% (389 mg)	97%	
84% (540 mg)	97% (377 mg)	97%	
84% (539 mg)	97% (363 mg)	97%	
83% (532 mg)	96% (350 mg)	97%	
83% (532 mg)	98% (342 mg)	97%	
83% (530 mg)	98% (335 mg)	97%	
82% (527 mg)	99% (330 mg)	97%	
82% (526 mg)	98% (325 mg)	97%	
82% (526 mg)	98% (320 mg)	97%	

Supplementary Table 5. Data of recycle experiment.



T1 (ppm)

Supplementary Figure 4. Comparison of recovered catalyst

6. Gram scale operation

To a Schlenk tube containing **Cat-8** (487.2 mg, 0.35 mmol, 5 mol%), ^{*m*}CPBA (1.718 g, 8.3 mmol, 1.2 equiv.) and EtOH (2.0 mL, 5 equiv.) were added CH₂Cl₂ (10 mL) and **12a** (1.512 g, 7 mmol, 1.0 equiv.). And the reaction was stirred at -20 °C for 48 h. The reaction mixture was quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was then extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated in vacuo, the residue was subsequently dissolved by 70 mL of MeOH, H₂O (15 mL) was finally added to precipitate the catalyst (467 mg, 96% recovery yield). The product **13a** was obtained in 1.19g with 80% yield and 99% *ee* via recrystallization.

HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 38.642 min for major isomer, t_R = 43.043 min for minor isomer



7. Spectra data of substrate.

.OH Cat-8 (15 mol%) OH OН ^mCPBA (1.5 equiv.) Ζ or or EtOH (5 equiv.) CH₂Cl₂ (0.02 M) R R 13, Z = O -20 °C, 24 h . 13m-o 12 **14**, $Z = H_2$

7.1 Characterization of enantioselective oxidative dearomatization

General procedure: To a Schlenk tube containing **Cat-8** (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.3 mmol, 1.5 equiv.), and EtOH (1 mmol, 5 equiv.) were added CH_2Cl_2 (10 mL) and **12** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 0 to -20 °C for 24 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the product **13**.



The reaction of 1-naphthol derivative **12a** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 ^oC for 24 h afforded compound **13a** (39.4 mg) in 92% yield as a

white solid. The title compound **13a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.03 (d, J = 7.6 Hz, 1H), 7.65 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 6.68 (d, J = 9.9 Hz, 1H), 6.23 (d, J = 9.9 Hz, 1H), 2.92 (ddd, J = 9.7, 11.2,17.6 Hz, 1H), 2.62 (ddd, J = 2.0, 9.6, 17.6 Hz, 1H), 2.44 (ddd, J = 2.0, 9.6, 13.2Hz, 1H), 2.22 (ddd, J = 9.8, 11.2, 13.2 Hz, 1H). ¹³**C NMR** (100 MHz, CDCl₃) δ 196.7, 176.7, 136.9, 135.8, 132.3,

129.0, 128.1, 128.0, 127.8, 127.4, 83.6, 31.3, 26.6. **HRMS** (ESI) m/z Calcd for $[C_{13}H_{10}O_3, M + H]^+$: 215.0703; Found: 215.0701.

Optical Rotation: $[\alpha]_{0}^{25}$ 186.2 (c = 1.0, CHCl₃). 98% *ee* (HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 39.007 min for major isomer, t_{R} = 43.250 min for minor isomer)





The reaction of 1-naphthol derivative **12b** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13a** (45.6 mg) in 92% yield as a white

solid. The title compound **13b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1).¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 7.7 Hz, 1H), 7.79-7.70 (m, 2H), 7.50 (m, 1H), 6.39 (s, 1H), 2.88 (ddd, J = 17.6, 11.2, 9.5 Hz, 1H), 2.61 (ddd, J = 17.7, 9.6, 2.3 Hz, 1H), 2.44 (ddd, J = 13.5, 9.6, 2.3 Hz, 1H), 2.24 (ddd, J = 13.4, 11.1, 9.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 194.9, 176.0, 135.9, 134.6, 131.8, 130.2, 129.2, 128.1, 127.3, 126.2, 83.6, 31.5, 26.6. HRMS (ESI) m/z Calcd for [C₁₃H₉ClO₃, M + H] ⁺: 249.0313, 251.0289; Found: 249.0313, 251.0287.

Optical Rotation: $[\alpha]_{p}^{25}$ 101.1 (c = 1.0, CHCl₃). 98% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 23.793 min for major isomer, *t_R* = 30.546 min for major isomer)





The reaction of 1-naphthol derivative **12c** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at 0 °C for 24 h afforded compound **13c** (49.5 mg) in 85% yield as a white solid. The title

compound **13c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 4.0 Hz, 2H), 7.59-7.41 (m, 1H), 6.66 (s, 1H), 2.87 (ddd, J = 17.6, 11.1, 9.6 Hz, 1H), 2.61 (ddd, J = 17.6, 9.6, 2.4 Hz, 1H), 2.45 (ddd, J = 13.3, 9.5, 2.4 Hz, 1H), 2.36-2.11 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) $\delta = 194.9$, 175.9, 136.0, 135.2, 133.5, 130.2, 128.9, 128.0, 127.4, 122.6, 84.4, 31.2, 26.5. HRMS (ESI) m/z Calcd for [C₁₃H₉O₃Br, M + H] ⁺: 292.9808, 294.9793; Found: 292.9804, 294.9786.

Optical Rotation: $[\alpha]_{p}^{25}$ 95.7 (c = 1.0, CHCl₃). 92% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 16.915 min for major isomer, *t_R* = 19.048 min for minor isomer).





The reaction of 1-naphthol derivative **12d** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13a** (58.7 mg) in 92% yield as a white solid. The title compound **13d**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 8.09 (dd, J = 7.8, 1.5 Hz, 1H), 8.02-7.88 (m, 2H), 7.66-7.56 (m, 2H), 7.53-7.42 (m, 3H), 7.39 (d, J = 7.8 Hz, 1H), 6.38 (s, 1H), 2.89 (ddd, J = 17.6, 11.3, 9.6 Hz, 1H), 2.60 (ddd, J = 17.6, 9.6, 2.2 Hz, 1H), 2.51 (ddd, J = 13.5, 9.5, 2.2 Hz, 1H), 2.28 (ddd, J = 13.4, 11.3, 9.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 195.4, 194.6, 176.0, 137.5, 136.1, 135.8, 134.4, 134.3, 134.2, 130.1, 129.9, 129.0, 128.5, 127.4, 127.0, 82.8, 31.2, 26.3. HRMS (ESI) m/z Calcd for [C₂₀H₁₄O₄, M + H] +: 319.0965; Found: 319.0964.

Optical Rotation: $[\alpha]_{p}^{25}$ -36.8 (c = 1.0, CHCl₃). 85% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 30.062 min for major isomer, *t_R* = 36.179 min for minor isomer).





The reaction of 1-naphthol derivative **12e** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at 0 °C for 80 h afforded compound **13e** (36.2 mg) in 71% yield as a white solid. The title compound **13e** was

isolated through chromatography on silica gel eluting with petroleum ether/ethyl

acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.03 (dd, J = 7.7, 1.6 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.65 (td, J = 7.7, 1.4 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 6.82 (s, 1H), 2.83 (ddd, J = 17.7, 11.4, 9.4 Hz, 1H), 2.65-2.58 (m, 1H), 2.54 (s, 3H), 2.44 (ddd, J = 13.7, 9.3, 2.1 Hz, 1H), 2.28 (ddd, J = 13.4, 11.5, 9.5 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 199.1, 195.2, 175.8, 137.3, 137.0, 135.7, 133.2, 129.7, 128.4, 127.7, 127.5, 83.3, 31.1, 29.0, 26.2. HRMS (ESI) m/z Calcd for [C₁₅H₁₂O₄, M + H] ⁺: 257.0807; Found: 257.0808.

Optical Rotation: $[\alpha]_{p}^{25}$ 180.1 (c = 1.0, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 30.95 min for minor isomer, t_R = 37.977 min for major isomer).





The reaction of 1-naphthol derivative **12f** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13f** (34.8 mg) in 60% yield as a white solid. The title compound **13f**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.09 (dd, J = 7.7, 1.5 Hz, 1H), 7.56 (td, J = 7.7, 1.5 Hz, 1H), 7.48-7.41 (m, 4H), 7.35 (dd, J = 7.4, 2.2 Hz, 2H), 7.16 (d, J = 7.8 Hz, 1H), 6.12 (s, 1H), 2.92 (ddd, J = 17.6, 11.3, 9.6 Hz, 1H), 2.63 (ddd, J = 17.6, 9.6, 2.2 Hz, 1H), 2.53 (ddd, J = 13.4, 9.5, 2.2 Hz, 1H), 2.28 (ddd, J = 13.4, 11.3, 9.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 196.6, 176.6, 140.0, 137.7, 137.5, 135.5, 130.7, 129.1, 128.9, 128.8,

128.6, 128.3, 127.7, 127.5, 83.9, 31.6, 26.9. **HRMS** (ESI) m/z Calcd for [C₁₉H₁₄O₃, M + H] ⁺: 291.1016; Found: 291.1015.

Optical Rotation: $[\alpha]_{b}^{35}$ 76 (c = 0.2, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 18.103 min for minor isomer, t_R = 29.030 min for major isomer).





The reaction of 1-naphthol derivative **12g** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13g** (48.6 mg) in 80% yield as a white solid. The title

compound **13g** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.4$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, J = 7.7 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.31 (dd, J = 12.9, 7.2 Hz, 2H), 7.24 (t, J = 7.5 Hz, 2H), 7.17 (d, J = 7.5 Hz, 3H), 5.82 (s, 1H), 3.81 (s, 2H), 2.79 (m, 1H), 2.48 (m, 1H), 2.36 (m, 1H), 2.18-2.03 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 196.7, 176.6, 137.5, 137.2, 135.9, 135.6, 130.9, 128.9, 128.9, 128.8, 128.1, 127.7, 126.9, 125.2, 83.8, 38.8, 31.6, 26.8. HRMS (ESI) m/z Calcd for [C₂₀H₁₆O₃, M + H] ⁺: 305.1172; Found: 305.1176.

Optical Rotation: $[\alpha]_{p}^{35}$ 104.2 (c = 1, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 28.602 min for major isomer, t_R = 51.283 min for minor isomer).





The reaction of 1-naphthol derivative **12h** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^mCPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13h** (28.8 mg) in 63% yield as a white solid. The title compound **13h**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J = 7.6 Hz, 1H), 7.67 (td, J = 7.6, 1.6 Hz, 1H), 7.47-7.37 (m, 2H), 6.01 (s, 1H), 2.87 (ddd, J = 17.6, 11.2, 9.7 Hz, 1H), 2.57 (ddd, J = 17.6, 9.5, 1.9 Hz, 1H), 2.39 (ddd, J = 13.5, 9.6, 2.3 Hz, 1H), 2.18 (s, 3H), 2.22-2.08 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 196.9, 176.8, 138.0, 135.7, 133.2, 129.0, 128.8, 127.9, 127.4, 125.0, 83.7, 31.6, 26.9, 19.4. HRMS (ESI) m/z Calcd for [C₁₄H₁₂O₃, M + H] +: 229.0859; Found: 229.0861.

Optical Rotation: $[\alpha]_{0}^{25}$ 104.2 (c = 1, CHCl₃). 93% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 20.420 min for minor isomer, t_R = 23.698 min for major isomer).





The reaction of 1-naphthol derivative **12i** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13i** (32.4 mg) in 92% yield as a white solid. The title compound **13i**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (dd, J = 7.7, 0.9 Hz, 1H), 7.66 (td, J = 7.8, 1.2 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 5.98 (s, 1H), 2.86 (ddd, J = 17.6, 11.3, 9.6 Hz, 1H), 2.62-2.52 (m, 3H), 2.39 (ddd, J = 13.2, 9.5, 1.9 Hz, 1H), 2.16 (ddd, J = 13.4, 11.4, 9.6 Hz, 1H), 1.23 (t, J = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) $\delta = 197.0$, 176.7, 138.3, 137.5, 135.6, 128.6, 128.1, 127.6, 127.2, 124.4, 83.9, 31.6, 26.9, 25.1, 12.4. HRMS (ESI) m/z Calcd for [C₁₅H₁₄O₃, M + H] +: 243.1016; Found: 243.1016. **Optical Rotation:** [α] ²⁵/₉ 176.6 (c = 1, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 18.914 min for minor isomer, t_R = 20.283 min for major isomer).





The reaction of 1-naphthol derivative **12j** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13j** (32.2 mg) in 63% yield as a white solid. The title compound **13j**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.4$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (dd, J = 7.7, 1.5 Hz, 1H), 7.65 (td, J = 7.6, 1.5 Hz, 1H), 7.46-

7.34 (m, 2H), 5.97 (s 1H), 2.85 (ddd, J = 17.6, 11.4, 9.5 Hz, 1H), 2.63-2.53 (m, 1H), 2.55-2.45 (m, 2H), 2.39 (ddd, J = 13.5, 9.5, 2.1 Hz, 1H), 2.15 (ddd, J = 13.5, 11.4, 9.5 Hz, 1H), 1.69-1.55 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 197.0, 176.7, 137.4, 136.8, 135.6, 128.6, 128.3, 128.1, 127.7, 124.7, 83.9, 34.3, 31.6, 26.8, 21.2, 14.0. **HRMS** (ESI) m/z Calcd for [C₁₆H₁₆O₃, M + H]⁺: 257.1172; Found: 257.1175.

Optical Rotation: $[\alpha]_{p}^{35}$ 169.8 (c = 1.0, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 12.951 min for minor isomer, t_R = 14.161 min for major isomer).





The reaction of 1-naphthol derivative **12k** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13k** (32.9 mg) in 61% yield and as a white solid. The title compound

13k was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.4$, petroleum ether/ethyl acetate = 3/1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.01 (dd, J = 7.7, 1.5 Hz, 1H), 7.65 (td, J = 7.6, 1.5 Hz, 1H), 7.47-7.34 (m, 2H), 5.98 (s, 1H), 2.85 (ddd, J = 17.6, 11.4, 9.5 Hz, 1H), 2.58 (td, J = 8.8, 8.0, 2.1 Hz, 1H), 2.52 (ddd, J = 9.1, 5.3, 2.0 Hz, 2H), 2.38 (ddd, J = 13.4, 9.5, 2.1 Hz, 1H), 2.15 (ddd, J = 13.4, 11.4, 9.5 Hz, 1H), 1.63-1.51 (m, 2H), 1.49-1.35 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 197.0, 176.7, 137.4, 137.1, 135.6, 128.6, 128.1, 127.7, 124.7, 83.9, 32.0, 31.6, 30.2, 26.9, 22.6, 14.0. HRMS (ESI) m/z Calcd for [$C_{17}H_{18}O_3$, M + H] ⁺: 271.1328; Found: 271.1325.

Optical Rotation: $[\alpha]_{p}^{25}$ 160.6 (c = 1.0, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 11.667 min for minor isomer, t_R = 12.305 min for major isomer).





The reaction of 1-naphthol derivative **12l** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13l**

(46.3 mg) in 95% yield as a white solid. The title compound **131** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 8.6 Hz, 1H), 6.88 (dd, J = 8.7, 2.5 Hz, 1H), 6.70 (d, J = 2.5 Hz, 1H), 6.59 (d, J = 9.9 Hz, 1H), 6.20 (d, J = 9.9 Hz, 1H), 3.89 (s, 3H), 2.93 (m, 1H), 2.58 (ddd, J = 17.6, 9.6, 2.1 Hz, 1H), 2.39 (ddd, J = 12.2, 9.6, 2.2 Hz, 1H), 2.16 (m, 1H). ¹³**C** NMR (100 MHz, CDCl₃) δ 195.0, 176.9, 165.7, 139.2, 133.4, 130.6, 128.0, 120.7, 114.5, 113.0, 83.1, 55.9, 31.7, 26.9. **HRMS** (ESI) m/z Calcd for [C₁₄H₁₂O₄, M + H] ⁺: 245.0808; Found: 245.0809.

Optical Rotation: $[\alpha]_{p}^{35}$ 138.3 (c = 1, CHCl₃). 97% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 75:25, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 12.767 min for minor isomer, t_R = 14.716 min for major isomer).





The reaction of 2-naphthol derivative **12m** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), HFIP (10 mmol, 50 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 ^oC for 24 h afforded compound **13m** (31.1 mg) in 73% yield as a white solid. The title compound **13m** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (3/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 7.7 Hz, 1H), 7.47 (dd, J = 9.3, 6.7 Hz, 2H), 7.43-7.33 (m, 2H), 6.17 (d, J = 9.9 Hz, 1H), 2.84 (ddd, J = 17.1, 11.6, 9.3 Hz, 1H), 2.71-2.60 (m, 2H), 2.15 (ddd, J = 14.0, 11.6, 9.7 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 176.6, 146.2, 140.7, 131.2, 129.9, 129.3, 129.3, 125.9, 122.7, 86.0, 35.9, 26.7. HRMS (ESI) m/z Calcd for [C₁₃H₁₀O₃, M + H] ⁺: 215.0698; Found: 215.0703.

Optical Rotation: $[\alpha]_{p}^{25}$ 264.2 (c = 1.0, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 11.667 min for minor isomer, t_R = 12.305 min for major isomer).





The reaction of 2-naphthol derivative **12n** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), HFIP (10 mmol, 50 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13n** (39.0 mg) in 80% yield as a white solid. The title compound **13n**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (3/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, J = 9.9 Hz, 1H), 7.24 (d, J = 2.7 Hz, 1H), 7.05 (d, J = 2.6 Hz, 1H), 6.85 (dd, J = 8.4, 2.6 Hz, 1H), 5.99 (d, J = 9.9 Hz, 1H), 3.83 (s, 3H), 2.80 (ddd, J

= 17.4, 11.7, 9.4 Hz, 1H), 2.66-2.57 (m, 2H), 2.11 (ddd, J = 13.8, 11.7, 9.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 197.6, 176.7, 162.3, 146.2, 143.1, 131.7, 122.3, 119.9, 114.5, 111.7, 86.1, 55.8, 36.2, 26.7. HRMS (ESI) m/z calcd for [C₁₄H₁₂O₄ + H]⁺: 245.0814, found: 245.0808.

Optical Rotation: $[\alpha]_{p}^{3}$ 232.2 (c = 1.0, CHCl₃). 95% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 28.241 min for minor isomer, t_R = 32.807 min for major isomer).





The reaction of 2-naphthol derivative **120** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), HFIP (10 mmol, 50 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **130** (39.0 mg) in 61% yield as a white solid. The title compound **130**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (3/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.58 (dd, J = 8.3, 2.0 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.45-7.37 (m, 2H), 6.20 (d, J = 10.0 Hz, 1H), 2.82 (ddd, J = 16.9, 11.6, 9.0 Hz, 1H), 2.68-2.59 (m, 2H), 2.11 (ddd, J = 14.3, 11.6, 9.7 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 196.9, 176.2, 144.5, 139.4, 133.8, 132.4, 131.1, 127.6, 123.9, 123.2, 85.5, 35.7, 26.6. HRMS (ESI) m/z calcd for [C₁₃H₉BrO₃ + H]⁺: 292.9808, 294.9788; Found: 292.9803, 294.9784.

Optical Rotation: $[\alpha]_{p}^{25}$ 172.5 (c = 0.5, CHCl₃). 93% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 25.737 min for minor isomer, t_R = 32.325 min for major isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14a** (30.0 mg) in 76% yield as a white solid. The title compound **14a** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.95 (dd, J = 7.8, 1.4 Hz, 1H), 7.53 (td, J = 7.5, 1.4 Hz, 1H), 7.32 (td, J = 7.6, 1.2 Hz, 1H), 7.17 (dd, J = 7.6, 1.1 Hz, 1H), 6.49 (d, J = 9.9 Hz, 1H), 6.16 (d, J = 9.9 Hz, 1H), 4.36-4.26 (m, 1H), 4.19-4.09 (m, 1H), 2.27-2.16 (m, 2H), 2.08-1.99 (m, 1H), 1.96-1.85 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 202.0, 137.5, 136.7, 134.8, 129.0, 128.1, 127.4, 127.2, 125.7, 84.3, 70.7, 36.6, 25.3. HRMS (ESI) m/z Calcd for [C₁₃H₁₂O₂, M + H] ⁺: 201.0910; Found: 201.0907.

Optical Rotation: $[\alpha]^{\frac{25}{9}}$ 247.2 (c = 0.5, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 6.749 min for major isomer, t_R = 8.22 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and m CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 ${}^{\circ}$ C for 16 h afforded compound **14b** (22.1 mg) in 52% yield as a solid. The title compound **14b** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, J = 7.7, 1.5 Hz, 1H), 7.59 (td, J = 7.6, 1.5 Hz, 1H), 7.34 (td, J = 7.7, 6.3 Hz, 2H), 5.97 (s, 1H), 4.30-4.21 (m, 1H), 4.17-4.06 (m, 1H), 2.19 (ddd, J = 11.8, 7.7, 3.9 Hz, 2H), 2.12 (s, 3H), 2.07-1.99 (m, 1H), 1.92-1.82 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 202.1, 138.5, 134.7, 133.2, 130.6, 129.0, 127.9, 127.4, 124.4, 84.1, 70.4, 36.4, 25.4, 19.4. HRMS (ESI) m/z Calcd for [C₁₄H₁₄O₂, M + H] ⁺: 215.1067; Found: 215.1070. **Optical Rotation:** [α] ⁵/₆ 216.2 (c = 0.5, CHCl₃). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 6.880 min for major isomer, t_R = 8.537 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 ^oC for 16 h afforded compound **14c** (28.7 mg) in 63% yield as oil. The title compound **14c** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, J = 7.7, 1.5 Hz, 1H), 7.58 (td, J = 7.6, 1.5 Hz, 1H), 7.39-7.31 (m, 2H), 5.96 (s, 1H), 4.32-4.25 (m, 1H), 4.17-4.11 (m, 1H), 2.55-2.47 (m, 2H), 2.24-2.16 (m, 2H), 2.07-1.99 (m, 1H), 1.91-1.83 (m, 1H), 1.21 (t, J = 7.4 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 202.3, 138.0, 135.9, 134.6, 131.3, 129.3, 127.8, 127.5, 123.9, 84.4, 70.5, 36.5, 25.3, 25.1, 12.6. **HRMS** (ESI) m/z Calcd for [C₁₅H₁₆O₂, M + H] ⁺: 229.1223; Found: 229.1225.

Optical Rotation: $[\alpha]_{0}^{\frac{35}{2}}$ 176.6 (c = 1, CHCl₃). 91% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 5.463 min for major isomer, t_R = 7.002 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 16 h afforded compound **14c** (30.1 mg) in 64% yield as oil. The title compound **14c** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, J = 7.7, 1.5 Hz, 1H), 7.57 (td, J = 7.6, 1.5 Hz, 1H), 7.38-7.28 (m, 2H), 5.95 (s, 1H), 4.31-4.24 (m, 1H), 4.17-4.08 (m, 1H), 2.50-2.41 (m, 2H), 2.24-2.14 (m, 2H), 2.06-1.97 (m, 1H), 1.93-1.83 (m, 1H), 1.66-1.56 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 202.3, 137.9, 134.6, 134.3, 132.5, 129.3, 127.7, 127.5, 124.1, 84.4, 70.4, 36.6, 34.5, 25.3, 21.3, 14.1. HRMS (ESI) m/z Calcd for [C₁₆H₁₈O₂, M + H] +: 243.1380; Found: 243.1381. **Optical Rotation:** $[\alpha]_{p}^{25}$ 169.8 (c = 1.0, CHCl₃). 92% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 4.875 min for major isomer, t_R = 5.992 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and m CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 ${}^{\circ}$ C for 16 h afforded compound **14e** (31.2 mg) in 61% yield as oil. The title compound **14e** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, J = 7.7, 1.5 Hz, 1H), 7.57 (td, J = 7.6, 1.5 Hz, 1H), 7.39-7.30 (m, 2H), 5.95 (s, 1H), 4.31-4.25 (m, 1H), 4.17-4.10 (m, 1H), 2.51-2.43 (m, 2H), 2.24-2.15 (m, 2H), 2.06-1.98 (m, 1H), 1.92-1.83 (m, 1H), 1.60-1.52 (m, 2H), 1.46-1.36 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 202.3, 137.9, 134.6, 134.6, 132.4, 129.4, 127.7, 127.5, 124.1, 84.4, 70.4, 36.6, 32.1, 30.4, 25.3, 22.7, 14.1. HRMS (ESI) m/z Calcd for [C₁₅H₁₂O₄, M + H]⁺: 257.0807; Found: 257.0808.

Optical Rotation: $[\alpha]_{p}^{25}$ 176.4 (c = 0.5, CHCl₃). 88% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 4.779 min for major isomer, t_R = 6.044 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and m CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 $^{\circ}$ C for 16 h afforded compound **14f** (41.1 mg) in 71% yield as a solid. The title compound **14f** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.99-7.87 (m, 1H), 7.43 (td, J = 7.6, 1.3 Hz, 1H), 7.28-7.14 (m, 7H), 5.91 (s, 1H), 4.25 (td, J = 7.7, 5.3 Hz, 1H), 4.12-4.03 (m, 1H), 3.79 (s, 2H), 2.25-2.10 (m, 2H), 2.04-1.94 (m, 1H), 1.92-1.81 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 202.0, 138.4, 137.6, 135.4, 134.6, 133.1, 129.3, 128.7, 128.7, 127.9, 127.5, 126.6, 124.8, 84.5, 70.6, 38.9, 36.7, 25.2. HRMS (ESI) m/z Calcd for [C₂₀H₁₈O₂, M + H] ⁺: 291.1380; Found: 291.1382. **Optical Rotation:** [α] ³⁵ 136.0 (c = 1, CHCl₃). 92% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 9.717 min for major isomer, t_R = 10.845 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 $^{\circ}$ C for 16 h afforded compound **14g** (38.6 mg) in 70% yield as oil. The title compound **14g** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.03 (dd, J = 7.7, 1.5 Hz, 1H), 7.51-7.33 (m, 7H), 7.09 (d, J = 7.8 Hz, 1H), 6.11 (s, 1H), 4.36-4.29 (m, 1H), 4.22-4.10 (m, 1H), 2.37-2.30 (m, 1H), 2.28-2.19 (m, 1H), 2.121.97 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 201.8, 138.7, 137.9, 137.6, 135.2, 134.4, 129.3, 129.0, 128.6, 128.2, 128.0, 127.6, 126.8, 84.5, 70.6, 36.8, 25.5. HRMS (ESI) m/z Calcd for [C₁₉H₁₆O₂, M + H] ⁺: 277.1223; Found: 277.1223.

Optical Rotation: $[\alpha]_{p}^{25}$ 98.0 (c = 0.5, CHCl₃). 84% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 5.887 min for major isomer, t_R = 7.905 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 $^{\circ}$ C for 16 h afforded compound **14h** (40.1 mg) in 74% yield as oil. The title compound **14h** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (d, J = 8.3 Hz, 1H), 7.71-7.61 (m, 2H), 7.48-7.36 (m, 1H), 6.62 (s, 1H), 4.32-4.22 (m, 1H), 4.19-4.08 (m, 1H), 2.31-2.13 (m, 2H), 2.13-1.91 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 199.8, 137.9, 135.7, 135.0, 129.4, 129.0, 128.2, 127.5, 119.8, 85.6, 70.8, 36.5, 25.4. HRMS (ESI) m/z Calcd for [C₁₃H₁₁O₂Br, M + Na] ⁺: 300.9840; Found: 300.9848.

Optical Rotation: $[\alpha]_{p}^{25}$ 137 (c = 0.5, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.437 min for major isomer, t_R = 8.982 min for minor isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and m CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 ${}^{\circ}$ C for 16 h afforded compound **14i** (34.8 mg) in 74% yield as oil. The title compound **14i** was isolated through

chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 7.6 Hz, 1H), 7.66-7.55 (m, 2H), 7.37 (td, J = 7.3, 1.7 Hz, 1H), 6.28 (s, 1H), 4.20 (m, 1H), 4.12-4.03 (m, 1H), 2.16 (m, 2H), 2.00 (ddd, J = 16.0, 8.9, 3.6 Hz, 1H), 1.94-1.82 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 199.7, 135.0, 134.9, 133.4, 129.4, 129.1, 128.9, 127.5, 125.5, 84.7, 70.7, 36.6, 25.4. HRMS (ESI) m/z Calcd for [C₁₃H₁₁O₂Cl, M + H] ⁺: 235.0520; Found: 235.0508.

Optical Rotation: $[\alpha]_{p}^{25}$ 110.5 (c = 0.5, CHCl₃). 95% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 5.164 min for major isomer, t_R = 6.914 min for minor isomer)





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14j** (33.6 mg) in 73% yield as a white solid. The title compound **14j** was

isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, J = 8.6 Hz, 1H), 7.25 (dd, J = 8.6, 2.5 Hz, 1H), 7.06 (d, J = 2.5 Hz, 1H), 6.87 (d, J = 9.8 Hz, 1H), 6.60 (d, J = 9.8 Hz, 1H), 4.78-4.67 (m, 1H), 4.62-4.51 (m, 1H), 4.29 (s, 3H), 2.73-2.59 (m, 2H), 2.51-2.41 (m, 1H), 2.39-2.25 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 200.4, 164.9, 139.7, 137.7, 129.9, 125.6, 122.4, 113.7, 112.1, 83.6, 70.8, 55.7, 37.0, 25.5. HRMS (ESI) m/z Calcd for [C₁₄H₁₄O₃, M + H] +: 231.1016; Found: 231.1016.

Optical Rotation: $[\alpha]_{p}^{3}$ 172.5 (c = 0.5, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 9.820 min for major isomer, t_R = 12.205 min for minor isomer).



7.2 Characterization of oxidative spirolactonization



General procedure: To a Schlenk tube containing **Cat-9** (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.), H₂O (2 mmol, 10 equiv.) and MeNO₂ (3 mL) were added **15** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at -10 °C for 72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. Finally, the organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the product **16**.



The reaction of the **15a** (55.4 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dried,

3.0 mL) at -10 °C for 72 h afforded compound **16a** (29.7 mg) in 54% yield as a white solid. The title compound **16a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 7.8 Hz, 1H), 7.68-7.59 (m, 2H), 7.44-7.28 (m, 7H), 7.02-6.96 (m, 2H), 6.96-6.89 (m, 7H), 6.03 (d, J = 9.6 Hz, 2H), 3.28 (s, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 194.2, 172.9, 145.0, 138.4, 135.5, 129.5, 129.3, 128.8, 128.7, 128.5, 128.2, 128.2, 127.8, 123.5, 123.2, 109.1, 64.5, 27.0, HRMS (ESI) m/z Calcd for [C₁₈H₁₃NO₂, M + H]⁺:276.1019; Found: 276.1017.
Optical Rotation: $[\alpha]_{p}^{25}$ -4.2 (c = 1.0, CHCl₃). 95% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.418 min for minor isomer, t_R = 11.691 min for major isomer).





The reaction of the **15b** (58.2 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dried, 3.0 mL) at -10 °C for 72 h afforded compound **16b** (34.68 mg) in

60% yield as a white solid. The title compound **16b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 7.7 Hz, 1H), 7.68-7.60 (m, 1H), 7.44-7.33 (m, 2H), 7.16-7.09 (m, 1H), 6.91 (d, J = 9.6 Hz, 1H), 6.81 (d, J = 8.0 Hz, 1H), 6.75 (s, 1H), 6.02 (d, J = 9.6 Hz, 1H), 3.26 (s, 3H), 2.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 172.8, 142.6, 138.5, 135.4, 132.9, 129.8, 129.5, 128.8, 128.8, 128.5, 128.2, 128.0, 127.8, 124.3, 108.9, 64.6, 27.1, 21.1., HRMS (ESI) m/z Calcd for [C₁₉H₁₅NO₂, M+H]⁺: 290.1176, found 290.1175. **Optical Rotation:** [α] $_{0.5}^{25}$ 54.9 (c = 1.0, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 6.351 min for minor isomer, t_R = 9.763 min for major isomer).





The reaction of the **15c** (66.6 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dried, 3.0 mL) at -10 °C for 72 h afforded compound **16c** (42.3 mg) in 64%

yield as a white solid. The title compound **16c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). ¹**H** NMR (400 MHz, CDCl₃) δ 8.01 (d, J = 7.7Hz, 1H), 7.69-7.61 (m, 1H), 7.41-7.33 (m, 3H), 6.97-6.89 (m, 2H), 6.85 (d, J = 8.3 Hz, 1H), 6.03 (d, J = 9.6 Hz, 1H), 3.26 (s, 3H), 1.22 (s, 9H).; ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 172.8, 146.6, 142.6, 138.5, 135.5, 129.7, 128.8, 128.8, 128.6, 128.2, 128.2, 127.9, 126.2, 120.7, 108.6, 64.9, 34.7, 31.6, 27.1., **HRMS** (ESI) m/z Calcd for [C₂₂H₂₁NO₂, M+H]⁺: 332.1646, found 332.1648.

Optical Rotation: $[\alpha]_{p}^{25}$ 88.6 (c = 0.5, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 4.505 min for minor isomer, t_R = 8.360 min for major isomer).





The reaction of the **15d** (61.4 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dried, 3.0 mL) at -10 °C for 72 h afforded compound **16d** (45.14 mg) in

74% yield as a white solid. The title compound **16d** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, J = 7.8, 1.4 Hz, 1H), 7.66-7.62 (m, 1H), 7.44-7.32 (m, 2H), 6.91 (d, J = 9.6 Hz, 1H), 6.88-6.77 (m, 2H), 6.56 (d, J = 2.3 Hz, 1H), 6.02 (d, J = 9.6 Hz, 1H), 3.69 (s, 3H), 3.25 (s, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 194.2, 172.5, 156.3, 138.4, 138.4, 135.5, 130.0, 129.4, 128.9, 128.5, 128.2, 128.2, 127.9, 113.7, 111.0, 109.4, 64.9, 55.9, 27.2., HRMS (ESI) m/z Calcd for [C₁₉H₁₅NO₃, M+H]⁺ :306.1125, found 306.1125. **Optical Rotation:** [α] $\frac{5}{0}$ 57 (c = 1, CHCl₃). 92% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 8.641 min for minor isomer, t_R = 15.589 min for major isomer).





The reaction of the **15e** (58.2 mg, 0.2 mmol, 1.0 equiv.), ^mCPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dry, 3.0 ml) at

-10 °C for 72 h afforded compound **16e** (31.2 mg) in 54% yield as oil. The title compound **16e** was isolated through chromatography on silica gel eluting with

petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.98 (d, J = 9.2 Hz, 1H), 7.68-7.60 (m, 1H), 7.42-7.29 (m, 3H), 7.02-6.87 (m, 4H), 6.04 (d, J = 9.6 Hz, 1H), 3.91-3.74 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 194.2, 172.6, 144.1, 138.4, 135.4, 129.5, 129.4, 129.0, 128.8, 128.8, 128.5, 128.2, 127.8, 123.7, 123.0, 109.3, 64.5, 35.6, 12.7., **HRMS** (ESI) m/z Calcd for [C₁₉H₁₅NO₂, M+H]⁺: 290.1176, found 290.1178.

Optical Rotation: $[\alpha]_{p}^{25}$ -14.7 (c = 0.5, CHCl₃). 95% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.225 min for minor isomer, t_R = 10.946 min for major isomer).





The reaction of the **15f** (67.4 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dry.,

3.0 mL) at -10 °C for 24 h afforded compound **16f** (27.1 mg) in 40% yield as oil. The title compound **16f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 7.7 Hz, 1H), 7.68-7.60 (m, 1H), 7.57-7.46 (m, 4H), 7.45-7.34 (m, 3H), 7.28-7.20 (m, 1H), 7.03-6.93 (m, 3H), 6.87 (d, J = 8.0 Hz, 1H), 6.19 (d, J = 9.6 Hz, 1H).; ¹³C NMR (100 MHz, CDCl₃) δ 194.1, 172.4, 145.1, 138.4, 135.5, 134.3, 129.8, 129.4, 129.3, 128.9, 128.9, 128.5, 128.4,

128.4, 128.2, 127.9, 126.8, 123.8, 123.6, 110.4, 64.6., **HRMS** (ESI) m/z Calcd for $[C_{23}H_{15}NO_2, M+Na]^+$: 338.1176, found 338.1178.

Optical Rotation: $[\alpha]_{p}^{25}$ -128.2 (c = 1, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 8.013 min for minor isomer, t_R = 26.230 min for major isomer).



7.3 Characterization of direct C(sp²)-H/C(sp³)-H cross-coupling



General procedure: To a Schlenk tube containing **Cat-3** (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) and H₂O (0.6 mmol, 3 equiv.) and MeCN (3 mL) were added **17** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 25 °C for 16 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the product **18**.



The reaction of the **17a** (56.4 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18a** (40.0 mg)

in 72% yield as a white solid. The title compound **18a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.36 (t, J = 8.4 Hz, 1H), 7.02 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 7.8 Hz, 1H), 6.88 (d, J = 6.2 Hz, 1H), 3.31 (s, 2H).; ¹³**C NMR** (100 MHz, CDCl₃) δ 172.3, 145.4, 129.7, 127.9, 124.0, 123.4, 109.0, 62.4, 27.2. **HRMS** (ESI) m/z Calcd for [C₁₇H₁₄N₂O₂, M+H]⁺: 279.1128, found 279.1129.

Optical Rotation: $[\alpha]_{b}^{\frac{35}{5}}$ -71 (c = 0.5, CHCl₃). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 11.836 min for major isomer, t_R = 27.463 min for minor isomer).





The reaction of the **17b** (62.0 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded

compound **18b** (48.9 mg) in 80% yield as a white solid. The title compound **18b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.15 (dd, J = 8.0, 1.7 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 6.71 (s, 1H), 3.29 (s, 3H), 2.25 (s, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 143.0, 133.1, 129.9, 128.0, 124.7, 108.6, 62.5, 27.1, 21.1., HRMS (ESI) m/z Calcd for [C₁₉H₁₈N₂O₂, M+H]⁺: 307.1441, found 307.1441.

Optical Rotation: $[\alpha]_{p}^{25}$ -111.2 (c = 0.5, CHCl₃). 82% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.751 min for minor isomer, t_R = 9.406 min for major isomer).





The reaction of the **17c** (71.6 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18c** (33.3 mg) in 47% yield as a

white solid. The title compound **18c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.57-7.21 (m, 7H), 7.15-6.89 (m, 5H), 6.84 (d, J = 7.9 Hz, 1H), 5.06 (t, J = 11.1 Hz, 2H), 3.36 (s, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 172.3, 145.5, 144.4, 135.3, 129.8, 129.6, 129.0, 127.9, 127.9, 127.8, 127.2, 124.0, 123.9, 123.5, 123.4, 110.0, 109.0, 62.4, 44.3, 27.1., HRMS (ESI) m/z Calcd for [$C_{23}H_{18}N_2O_2$, M+H]⁺:355.1441, found 355.1440.

Optical Rotation: $[\alpha]_{p}^{25}$ -29.2 (c = 0.5, CHCl₃). 89% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 22.980 min for major isomer, t_R = 26.662 min for minor isomer).





The reaction of the **17d** (78.4 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18d** (31.8

mg) in 41% yield as a white solid. The title compound **18d** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.33 (m, 5H), 7.32-7.27 (m, 1H), 7.25-7.22 (m, 1H), 7.00 (td, J = 7.6, 1.0 Hz, 1H), 6.96-6.84 (m, 3H), 6.81 (d, J = 7.9 Hz, 1H), 5.11-4.89 (m, 2H), 3.32 (s, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 171.8, 144.4, 144.1, 135.1, 129.9, 129.8, 129.3, 129.1, 128.8, 127.9, 127.2, 127.2, 124.5, 124.1, 123.6, 110.2, 109.9, 62.3, 44.5, 27.3., HRMS (ESI) m/z Calcd for [C₂₃H₁₇ClN₂O₂, M+H]⁺: 389.1051, 391.1022, found 389.1057, 391.1039

Optical Rotation: $[\alpha]_{p}^{25}$ -74.8 (c = 0.5, CHCl₃). 86% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 15.267 min for major isomer, t_R = 21.668 min for minor isomer).





The reaction of the **17e** (83.2 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18e** (51.0 mg) in 62% yield as a white solid. The title compound **18e** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹**H NMR** (400 MHz, CDCl₃) δ 8.14 (dt, J = 8.3, 1.4 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.40-7.34 (m, 4H), 7.30 (p, J = 2.9 Hz, 1H), 7.24 (dd, J = 7.8, 1.4 Hz, 1H), 7.05-6.97 (m, 2H), 6.84 (dd, J = 23.5, 7.7 Hz, 2H), 5.13-4.89 (m, 2H), 3.85 (s, 3H), 3.37 (s, 3H).; ¹³**C NMR** (100 MHz, CDCl₃) δ 172.5, 172.0, 166.5, 149.5, 144.5, 135.1, 132.4, 129.9, 129.1, 127.9, 127.2, 127.2, 125.5, 125.4, 124.1, 123.7, 110.2, 108.6, 62.1, 52.3, 44.5, 27.4. **HRMS** (ESI) m/z Calcd for [C₂₅H₂₀N₂O₄, M+H]⁺ : 413.1496, found 413.1496.

Optical Rotation: $[\alpha]_{p}^{3}$ -176.6 (c = 0.5, CHCl₃). 87% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 22.257 min for major isomer, t_R = 38.566 min for minor isomer).





The reaction of the **17f** (74.4 mg, 0.2 mmol, 1.0 equiv.), ^{*m*}CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18f** (38.3 mg) in

52% yield as a white solid. The title compound **18f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.57-7.33 (m, 5H), 7.29 (d, J = 6.9 Hz, 1H), 7.22 (t, J = 7.7 Hz, 1H), 7.01 (dq, J = 14.2, 7.5 Hz, 3H), 6.90 (dd, J = 17.3, 7.4 Hz, 2H), 6.80 (d, J = 7.9 Hz, 1H), 5.11-4.88 (m, 2H),

4.02-3.75 (m, 2H), 1.37 (t, J = 7.2 Hz, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 171.9, 144.6, 144.4, 135.3, 129.7, 129.5, 129.0, 128.2, 128.1, 127.8, 127.2, 124.1, 123.8, 123.4, 123.3, 110.0, 109.1, 62.4, 44.3, 35.6, 12.8., **HRMS** (ESI) m/z Calcd for [C₂₄H₂₀N₂O₂, M+H]⁺: 368.1598, found 369.1604.

Optical Rotation: $[\alpha]_{p}^{25}$ -11.6 (c = 0.5, CHCl₃). 89% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 12.404 min for major isomer, t_R = 37.330 min for minor isomer).



7.4 Characterization of oxidative fluorination of keto esters.



General procedure: To a Teflon tube containing β -ketoesters **19** (0.20 mmol, 1.0 equiv.), **Cat-38** (0.03 mmol, 15 mol%), and CHCl₃ (8 mL) were added NEt₃·3HF (2 mmol, 10 equiv.) and ^mCPBA (0.3 mmol, 1.5 equiv.) in turn, the reaction mixture was stirred at 25 °C for 24-72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the desired product **20**.



The reaction of the β -keto ester **19a** (44.8 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 24 h afforded

compound **20a** (27.6 mg) in 57% yield as a white solid. The title compound **20a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.80 (d, J = 2.1 Hz, 1H), 7.66 (dd, J = 8.2, 2.1 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 3.81 (s, 3H), 3.77 (dd, J = 17.7, 10.8 Hz, 1H), 3.41 (dd, J = 22.9, 17.7 Hz, 1H).; ¹³**C** NMR (100 MHz, CDCl₃) δ 194.1 (d, ² $_{J_{C}-F} = 18.3$ Hz), 167.4 (d, ² $_{J_{C}-F} = 27.7$ Hz), 149.0 (d, ³ $_{J_{C}-F} = 3.7$ Hz), 136.9, 135.3, 134.8(d, ³ $_{J_{C}-F} = 1.4$ Hz), 128.0, 125.5, 94.9 (d, ¹ $_{J_{C}-F} = 202.8$ Hz), 53.6, 38.0 (d, ² $_{J_{C}-F} = 24.0$ Hz)., ¹⁹**F** NMR (376 MHz, CDCl₃) δ -164.16. **GC-MS (EI)** m/z Calcd for [C₁₁H₈ClFO]⁺: 242.0, 244.0; found 242.0, 244.0

Optical Rotation: $[\alpha]_{0}^{\frac{35}{9}}$ 4.2 (c = 0.5, CHCl₃). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 15.678 min for major isomer, t_R = 16.611 min for minor isomer).





The reaction of the β -keto ester **19b** (47.6mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 24 h afforded

compound **20b** (26.6 mg) in 52% yield as oil. The title compound **20b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($\mathbf{R}_{\rm f} = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 2.4 Hz, 1H), 7.66 (dd, J = 8.1, 2.4 Hz, 1H), 7.46 (d, J = 8.3 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.75 (dd, J = 17.8, 11.0 Hz, 1H), 3.39 (dd, J = 23.0, 17.7 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H); ¹³**C** NMR (100 MHz, CDCl₃) δ 194.3 (d, ² $_{J_{C-F}} = 18.2$ Hz), 167.0 (d, ² $_{J_{C-F}} = 27.6$ Hz), 149.1 (d, ³ $_{J_{C-F}} = 4.4$ Hz), 136.8, 135.2, 134.8, 127.9, 125.4, 94.8 (d, ¹ $_{J_{C-F}} = 202.7$ Hz), 62.9, 38.0 (d, ² $_{J_{C-F}} = 24.0$ Hz), 14.1. ¹⁹**F** NMR (376 MHz, CDCl₃) δ -164.04. **GC-MS (EI)** m/z Calcd for [C₁₂H₁₀ClFO₃]⁺: 256.0, found 256.0. **Optical Rotation:** [α] ³⁵ 2.7 (c = 1.0, CHCl₃). 88% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 0.5 mL/min, 30 °C, wavelength = 254 nm, t_R = 11.849 min for major isomer, t_R = 13.353 min for minor isomer).





The reaction of the β -keto ester **19c** (60.0 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 24 h afforded

compound **20c** (31.8 mg) in 50% yield as oil. The title compound **20c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.79 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 8.2, 2.1 Hz, 1H), 7.44 (d, J = 8.1 Hz, 1H), 7.37-7.30 (m, 3H), 7.30-7.24 (m, 2H), 5.30-5.19 (m, 2H), 3.73 (dd, J = 17.7, 11.1 Hz, 1H), 3.39 (dd, J = 22.8, 17.7 Hz, 1H).; ¹³**C NMR** (100 MHz, CDCl₃) δ 194.1(d, ² $_{J_{C-F}} = 18.7$ Hz), 166.9 (d, ² $_{J_{C-F}} = 28.3$ Hz), 149.0 (d, ³ $_{J_{C-F}} = 3.7$ Hz), 136.9, 135.3, 134.8, 134.6, 128.8, 128.3, 127.9, 125.4, 94.8 (d, ¹ $_{J_{C-F}} = 203.0$ Hz), 68.2, 37.9 (d, ² $_{J_{C-F}} = 24.2$ Hz). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -164.02. **HRMS** (ESI) m/z Calcd for [C₁₇H₁₂ClFO₃, M+Na]⁺:341.0369, found 341.0353.

Optical Rotation: $[\alpha]_{p}^{3}$ -1.6 (c = 0.25, CHCl₃). 85% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 8.390 min for major isomer, t_R = 9.912 min for minor isomer).





The reaction of the β -keto ester **19d** (68.8 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8 mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 24 h afforded

compound **20d** (29.7 mg) in 41% yield as white solid. The title compound **20d** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($\mathbf{R}_{\rm f} = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.76 (s, 1H), 7.65-7.60 (m, 1H), 7.44 (d, J = 8.1 Hz, 1H), 3.69 (dd, J = 17.6, 10.0 Hz, 1H), 3.35 (dd, J = 22.5, 17.6 Hz, 1H), 2.13 (s, 3H), 2.02 (d, J = 3.5 Hz, 6H), 1.60 (t, J = 3.4 Hz, 6H); ¹³**C** NMR (100 MHz, CDCl₃) δ 194.8 (d, ² $J_{C-F} = 18.9$ Hz), 165.4 (d, ² $J_{C-F} = 27.6$ Hz), 149.2 (³ J_{C-F} , J = 3.6 Hz), 136.5, 135.1, 134.9, 127.8, 125.1, 94.5 (d, ¹ $J_{C-F} = 202.7$ Hz), 84.6, 41.1, 38.1 (d, ² $J_{C-F} = 24.0$ Hz), 35.9, 30.9. ¹⁹**F** NMR (376 MHz, CDCl₃) δ -163.60. **HRMS** (ESI) m/z Calcd for [C₂₀H₂₀ClFO₃, M+Na]⁺: 385.0977, found 385.0973.

Optical Rotation: $[\alpha]_{p}^{25}$ 10.8 (c = 0.5, CHCl₃). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.437 min for major isomer, t_R = 8.714 min for minor isomer).





The reaction of the β -keto ester **19e** (38 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 48 h afforded compound **20e** (20.8

mg) in 50% yield as oil. The title compound 20e was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1).

(R_f = 0.6, petroleum ether/ethyl acetate = 5/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 7.8 Hz, 1H), 7.68 (m, 1H), 7.49 (m, 1H), 7.46-7.39 (m, 1H), 3.84-3.72 (m, 1H), 3.76 (s, 3H), 3.41 (dd, J = 23.5, 17.7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 195.3 (d, ² $J_{C-F} = 18.2$ Hz), 167.7 (d, ² $J_{C-F} = 28.3$ Hz), 150.9 (d, ³ $J_{C-F} = 3.6$ Hz), 136.9, 133.1, 128.7, 126.7 (d, ³ $J_{C-F} = 1.04$ Hz), 125.6, 94.6 (d, ¹ $J_{C-F} = 201.3$ Hz), 53.3, 38.2 (d, ² $J_{C-F} = 24.0$ Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -164.53. HRMS (ESI) m/z Calcd for [C₁₁H₉FO₃, M+Na]⁺:231.0428, found 231.0422.

Optical Rotation: $[\alpha]_{p}^{25}$ -17.0 (c = 1.0, CHCl₃). 80% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 8.124 min for major isomer, t_R = 9.052 min for minor isomer).





The reaction of the β -keto ester **19f** (72.4mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 24 h afforded compound **20f** (25.8

mg) in 58% yield as oil. The title compound **20f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.84 (d, J = 7.7Hz, 1H), 7.71 (td, J = 7.5, 1.2 Hz, 1H), 7.54-7.43 (m, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.79 (dd, J = 17.6, 11.5 Hz, 1H), 3.44 (dd, J = 23.3, 17.6 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H).; ¹³**C NMR** (100 MHz, CDCl₃) δ 195.5 (d, ² $J_{C-F} = 18.8$ Hz), 167.5 (d, ² $J_{C-F} = 27.6$ Hz), 151.1 (d, ³ $J_{C-F} = 3.6$ Hz), 136.9, 133.4, 128.8, 126.7, 125.8, 94.6 (d, ¹ $J_{C-F} = 201.3$ Hz), 62.8, 38.4 (d, ${}^{2}J_{C-F} = 24.0$ Hz), 14.2. ¹⁹F NMR (376 MHz, CDCl₃) δ -164.44. HRMS (ESI) m/z Calcd for [C₁₂H₁₁FO₃, M+Na]⁺:245.0584, found 245.0578.

Optical Rotation: $[\alpha]_{p}^{25}$ -3.5 (c = 0.5, CHCl₃). 84% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 8.124 min for major isomer, t_R = 9.052 min for minor isomer).





The reaction of the β -keto ester **19g** (40.8 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8 mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 24 h afforded

compound **20g** (23.9 mg) in 53% yield as a white solid. The title compound **20g** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.53-7.38 (m, 3H), 3.81 (s, 3H), 3.76 (dd, J = 17.3, 10.6 Hz, 1H), 3.40 (dd, J = 23.0, 18.6 Hz, 1H).; ¹³**C NMR** (100 MHz, CDCl₃) δ 194.5 (dd, ² $J_{C-F} = 18.8$, 3.5 Hz), 167.5 (d, ² $J_{C-F} = 27.7$ Hz), 162.9 (d, ¹ $J_{C-F} = 250.6$ Hz), 146.5 (dd, ³ $J_{C-F} = 3.5$, 2.3 Hz), 135.0 (d, ³ $J_{C-F} = 7.9$ Hz), 128.3 (d, ³ $J_{C-F} = 8.0$ Hz), 124.8 (d, ² $J_{C-F} = 23.6$ Hz), 111.5 (d, ² $J_{C-F} = 22.5$ Hz), 95.1 (d, ¹ $J_{C-F} = 202.4$ Hz), 53.5, 37.8 (d, ² $J_{C-F} = 24.0$ Hz). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -163.95, δ -111.89. **HRMS** (ESI) m/z Calcd for [C₁₁H₈FO₃, M+H]⁺: 227.0514, found 227.0508.

Optical Rotation: $[\alpha]_{b}^{\frac{35}{5}}$ 3.2 (c = 0.5, CHCl₃). 83% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.943 min for major isomer, t_R = 8.470 min for minor isomer).





The reaction of the β -keto ester **19h** (53.6 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8 mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 24 h afforded

compound **20h** (36.4 mg) in 64% yield as a white solid. The title compound **20h** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.94 (d, J = 2.0 Hz, 1H), 7.80 (dd, J = 8.2, 2.0 Hz, 1H), 7.40 (d, J = 8.2 Hz, 1H), 3.80 (s, 3H), 3.74 (dd, J = 17.8, 10.7 Hz, 1H), 3.37 (dd, J = 22.9, 17.8 Hz, 1H).; ¹³**C NMR** (100 MHz, CDCl₃) δ 194.0 (d, ² $_{J_{C-F}} = 18.3$ Hz), 167.4 (d, ² $_{J_{C-F}} = 27.7$ Hz), 149.4 (d, ³ $_{J_{C-F}} = 3.7$ Hz), 139.7, 135.0, 128.5, 128.3, 122.9, 94.7 (d, ¹ $_{J_{C-F}} = 202.8$ Hz), 53.5, 38.0 (d, ² $_{J_{C-F}} = 24.2$ Hz). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -164.2. **GC-MS** (EI) m/z Calcd for [C₁₁H₈BrFO₃]⁺: 286.0, 288.0; found 286.0, 288.0.

Optical Rotation: $[\alpha]_{0}^{35}$ 4.8 (c = 0.5, CHCl₃). 85% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 8.506 min for major isomer, t_R = 9.517 min for minor isomer).





The reaction of the β -keto ester **19i** (40.8 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8 mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 48 h afforded

compound **20i** (21.3 mg) in 48% yield as white solid. The title compound **20i** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.67 (d, J = 7.9 Hz, 1H), 7.28-7.21 (m, 2H), 3.75 (s, 3H), 3.70 (dd, J = 17.8, 11.2 Hz, 1H), 3.33 (dd, J = 23.4, 17.7 Hz, 1H), 2.43 (s, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 194.6 (d, ² $J_{C-F} = 18.2$ Hz), 167.9 (d, ² $J_{C-F} = 27.9$ Hz), 151.4 (d, ³ $J_{C-F} = 3.8$ Hz), 148.8, 130.9, 130.1, 127.0, 125.5, 95.0 (d, ¹ $J_{C-F} = 201.2$ Hz), 53.3, 38.1 (d, ² $J_{C-F} = 23.9$ Hz), 22.4. ¹⁹F NMR (376 MHz, CDCl₃) δ -164.30. HRMS (ESI) m/z Calcd for [C₁₂H₁₁FO₃, M+Na]⁺:245.0584, found 245.0576.

Optical Rotation: $[\alpha]_{p}^{\frac{30}{2}}$ -3.5 (c = 0.5, CHCl₃). 85% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 9.458 min for major isomer, t_R = 10.943 min for minor isomer).





The reaction of the β -keto ester **19j** (44.0 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 72 h

afforded compound **20j** (21.3 mg) in 50% yield as a white solid. The title compound **20j** was isolated through chromatography on silica gel eluting with petroleum

ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H NMR** (400 MHz, CDCl₃) δ 7.77 (d, J = 8.6 Hz, 1H), 6.98 (dd, J = 8.6, 2.2 Hz, 1H), 6.91 (d, J = 2.2 Hz, 1H), 3.92 (s, 3H), 3.81 (s, 3H), 3.75 (dd, J = 17.7, 11.0 Hz, 1H), 3.38 (dd, J = 23.0, 17.7 Hz, 1H).; ¹³**C NMR** (100 MHz, CDCl₃) δ 193.1 (d, ² $J_{C-F} =$ 18.2 Hz), 168.1 (d, ² $J_{C-F} = 28.3$ Hz), 167.0, 154.2 (d, ³ $J_{C-F} = 3.7$ Hz), 127.7, 126.4, 116.9, 109.9, 95.2 (d, ¹ $J_{C-F} = 201.3$ Hz), 56.1, 53.4, 38.4 (d, ² $J_{C-F} = 24.0$ Hz). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -163.60. **HRMS** (ESI) m/z Calcd for [C₁₂H₁₁FO₄, M+Na]⁺:261.0534, found 261.0528

Optical Rotation: $[\alpha]_{p}^{25}$ 37 (c = 1, CHCl₃). 83% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 20.311 min for minor isomer, t_R = 23.065 min for major isomer).





The reaction of the β -keto ester **19k** (44.8 mg, 0.20 mmol, 1.0 equiv.), ^{*m*}CPBA (61.8 mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), NEt₃·3HF (334 uL, 2 mmol, 10 equiv.) in CHCl₃ (8 mL) at 25 °C for 48 h afforded

compound **20k** (22.3 mg) in 46% yield as a white solid. The title compound **20k** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ¹**H** NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 8.2 Hz, 1H), 7.49 (s, 1H), 7.43 (d, J = 10.0 Hz, 1H), 3.79 (s, 3H), 3.77 (dd, J = 17.9, 11.1 Hz, 1H), 3.40 (dd, J = 23.0, 17.8 Hz, 1H).; ¹³**C** NMR (100 MHz, CDCl₃) δ 193.8 (d, ² $J_{C-F} = 18.2$ Hz), 167.4 (d, ² $J_{C-F} = 28.2$ Hz), 152.3 (d, ³ $J_{C-F} = 4.2$ Hz), 143.6, 131.7, 129.7, 127.0, 126.8, 94.6 (d, ¹ $J_{C-F} = 202.4$ Hz), 53.5,

38.0 (${}^{2}J_{C-F}$, J = 24.1 Hz). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -164.07. **GC-MS (EI)** m/z Calcd for [C₁₁H₈ClFO]⁺: 242.0, 244.0; found 242.0, 244.0

Optical Rotation: $[\alpha]_{p}^{3}$ 33 (c = 1, CHCl₃). 80% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 10.818 min for major isomer, t_R = 13.117 min for minor isomer).



8. Investigation of the significance for H-bond interactions and

tunable chiral pocket

Supplementary Table 6. Investigation of the significance for H-bond interactions and tunable chiral pocket.



General procedure for the control experiment of oxidative dearomatization: To a Schlenk tube containing Cat (0.03 mmol, 15 mol%), ^{*m*}CPBA (0.3 mmol, 1.5 equiv.) and EtOH (1 mmol, 5 equiv.) were added CH₂Cl₂ (10 mL) and **12a** (0.2 mmol). The reaction mixture was stirred at -20 °C for 24 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated in vacuo and then the residue was purified by silica gel column chromatography to afford the product **13a**.

Experiment of oxidative dearomatization using **Cat-41**: 15% *ee* (HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C,

wavelength = 254 nm, t_R = 39.989 min for major isomer, t_R = 44.491 min for minor isomer)



Experiment of oxidative dearomatization using **Cat-12**: 97% *ee* (HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 40.588 min for major isomer, t_R = 44.669 min for minor isomer)



General procedure for the control experiment of oxidative spirolactonization. To a Schlenk tube containing Cat (0.03 mmol, 15 mol%), ^mCPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.), H₂O (2 mmol, 10 equiv.) and MeNO₂ (3 mL) were added **15a** (0.2 mmol). The reaction mixture was stirred at -10 °C for 72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. Finally, the organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated *in vacuo* and then the residue was purified by silica gel column chromatography to afford the product **16a**. Experiment of oxidative spirolactonization using **Cat-43:** 55% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.651 min for minor isomer, t_R = 11.785 min for major isomer).



Experiment of oxidative spirolactonization using **Cat-13:** 93% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.675 min for minor isomer, t_R = 11.887 min for major isomer).



Experiment of oxidative spirolactonization using **Cat-44**: 81% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.174 min for minor isomer, t_R = 10.864 min for major isomer).



General procedure for the control experiment of direct $C(sp^2)$ -H/C(sp³)-H crosscoupling. To a Schlenk tube containing Cat (0.03 mmol, 15 mol%), ^mCPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) and H₂O (0.6 mmol, 3 equiv.) and MeCN (3 mL) were added **17a** (0.2 mmol). The reaction mixture was stirred at 25 °C for 16 hours. which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo* and then the residue was purified by silica gel column chromatography to afford the product **18a**.

Experiment of direct C(sp²)-H/C(sp³)-H cross-coupling using **Cat-45**: 33% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 11.907$ min for major isomer, $t_R = 27.393$ min for minor isomer).



Experiment of direct C(sp²)-H/C(sp³)-H cross-coupling using **Cat-5**: 89% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 11.770$ min for major isomer, $t_R = 27.268$ min for minor isomer).



Experiment of direct C(sp²)-H/C(sp³)-H cross-coupling using **Cat-46**: 72% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 12.011 min for major isomer, t_R = 28.677min for minor isomer).



General procedure for the control experiment of fluorinated keto esters. To 25 mL Teflon tube containing β -ketoesters **19a** (0.20 mmol), **Cat** (0.03 mmol, 15 mol%), and CHCl₃ (8 mL) were added. Subsequently, NEt₃·3HF (2 mmol, 10 equiv.) and ^mCPBA (0.3 mmol, 1.5 equiv.) was loaded in turn. The reaction mixture was stirred at 25 °C for 24 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo* and then the residue was purified by silica gel column chromatography to afford desired products **20a**.

Experiment of fluorinated keto esters using **Cat-48**: 80% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 15.839$ min for major isomer, $t_R = 16.792$ min for minor isomer).



Experiment of fluorinated keto esters using **Cat-49**: 52% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 15.804$ min for major isomer, $t_R = 16.775$ min for minor isomer).



9. Possible mechanism for the reactions

9.1 Possible mechanism DFT Calculation of the enantioselective oxidative dearomatization.

Supplementary scheme 1. Proposed mechanism for enantioselective oxidative dearomatization.



The proposed mechanism for enantioselective oxidative dearomatization is depicted in **Supplementary scheme 1**. First, conformationally flexible aryl iodide ArI (**Cat-8**) was oxidated to the active catalyst ArI^{III} (**Cat-8(III**)) which shows the formation of a C_2 -symmetric helical chiral environment around the iodine(III) center after forming intramolecular hydrogen bonds between the amide proton and ethoxy ligand. By attending of naphthol, **Ts12a-1** is formed, followed by naphtholate iodine(III) intermediate **Ts12a-2** which is obtained *via* naphthol oxygen attacking. After passing through the transition state, the product mainly presents *R* enantiomer. Because the aromatic moiety of the mesityl group can adjust its direction to enhance π - π stacking interaction with the naphthol, and the substrate can fit in the helical chiral environment which gives additional stabilization to **Ts12a-(R)**. The steric repulsion of the mesityl group and the hydrogen bonds created by additives contribute to nucleophilic attack of the carboxylic acid group on *Si* face of the naphthol.

Otherwise, nucleophilic attack of the carboxyl group on Re face of the naphthol ruin the helical chiral environment, and it leads to the poor stabilization of the transition state (**Ts12a-(***S*)), so it shows major *R* enantiomer of the product.^[7,16]





Density functional theory (DFT) studies were performed to study reaction mechanism, as shown in **Supplementary scheme 2**. The formation of iodine(III) intermediate **Int-B** is kinetically viable through **TS-A** (ΔG^{\ddagger} : 13.5 kcal/mol). The following proton transfer step occurs to generate **Int-C**, with a reaction barrier of 15.5 kcal/mol (**Int-B** to **TS-B**). Finally, the cyclization occurs to produce **1P** via **TS-C** (ΔG^{\ddagger} : 2.6 kcal/mol). This mechanistic process is similar with the reaction route calculated by Xue's group.^[16]

9.2 Possible mechanism of the asymmetric spirocyclization reaction.

Cat-9 (15 mol%) CPBA (1.3 equiv FE (50 equiv.) H₂O (10 equiv.) eNO₂, -10 °C, 72 h _CH₂CF 70 15a 15a-1 15a-2 15a-3 Aromatization CF₃H₂C CF H2CC 16a repulsion Ts15a-2(*R*) Ts15a-2(S) major mino

Supplementary scheme 3. Proposed mechanism for enantioselective oxidative spirolactonization.

The plausible reaction mechanism of oxidative spirolactonization is proposed in **Supplementary scheme 3**. The chiral aryl iodine **Cat-9** is oxidized into a hypervalent phenyl- λ^3 -iodane by ^mCPBA. Subsequent formation of naphtholate iodine(III) **15a-1** is carried out by attacking of naphthol oxygen. Then ligand exchange with 2,2,2-trifluoroethanol and water is undergoing to generate **15a-2**. The configuration of the product is mainly determined by the transition state **Ts15a-2**. Since *p*-nitrobenzamide can changes its orientation to enhance the π - π interaction between *p*-nitrobenzamide and naphthamide moiety, the substrate is fit to the helical chiral environment which increases the enantioselectivities. In this transition state, the *Si* face of the naphthamide moiety is open for the nucleophilic attack of the benzene. In contrast, the *Re* face is blocked by *p*-nitrobenzamide moiety in catalyst, contributing to the major *S* enantiomer of the product. The resulting compound **15a-3** is rearomatized to get the final product **16a**.^[10]

9.3 Possible mechanism of the direct C(sp2)-H/C(sp3)-H oxidative cross-coupling.

Supplementary scheme 4. Proposed mechanism for the direct $C(sp^2)$ -H/C(sp³)-H cross-coupling.



The plausible mechanism of direct $C(sp^2)$ -H/ $C(sp^3)$ -H cross-coupling is depicted in **Supplementary scheme 4**. First, the chiral aryl iodine **Cat-3** is oxidized into a hypervalent phenyl- λ^3 -iodane by ^mCPBA. Then nucleophilic attack on the iodine center by the carbonyl oxygen in **17a** affords intermediate **17a-2**. After capturing α proton by the generated trifluoroacetate anion, enamine **17a-3** is undergoing the electrocyclic ring closure, along with the cleavage of the I-O bond, and occurs in oxindole **17a-4**. Then another nucleophilic attack on the iodine center is taking place on the carbonyl oxygen to form intermediate **17a-5**, and result in the electrocyclic ring closure to form product **18a**. The configuration of the product is mainly determined by the transition state **Ts17a-5**. Comparing to the results demonstrated by **Cat-5** and **Cat-46** in scheme 5, we find substituent on side arm (CH₂OTBDPS) plays key role in enantioselectivities. Combining optimization of catalysts, we presumed that the moiety of the substrate is remote from the bulky tertiary butyl substituent and benzene ring of the catalyst, and the *Si* face of the 2-indololate moiety is open to nucleophilic

attack by the benzene ring on substrate, thus favorably giving **18a**. In contrast, the *Re* face of the 2- indololate moiety is shielded by the bulky tertiary butyl substituent and benzene ring on catalyst, thus leading to the generation of the enantiomer in a minor amount.^[11,17]

9.4 Possible mechanism for the asymmetric oxidative fluorination of keto esters.

Supplementary scheme 5. Proposed mechanism for the oxidative fluorination of keto esters.



The hypothesized mechanism for the oxidative fluorination of keto esters is presented in **Supplementary scheme 5**. The first step involves the reaction of the enol form of substrate **19f** with hypervalent iodine to abstract the H atom from **19f** *via* the transition state **19f-1** and **19f-2** with formation of an O-I bonded hypervalent

iodine intermediate 19f-3. Then hypervalent iodine intermediate 19f-5 which is enantioselectivity determining transition state is formed via transfer of the hypervalent iodine fragment from the carboxylic O atom to the α -C atom through 19f-4. The optimization of catalysts in Supplementary Table 4 shows that bulky substituent especially aromatic ring to modify amino groups is good for enantioselectivities. And the results demonstrated by Cat-38 and Cat-48 in scheme 5 present nitrobenzene on catalyst is essential to enantioselectivities as well. Thus, we presumed the carbonyl moiety of the indanone is remote from the bulky substituent which bring by tribromobenzene of the catalyst, and the enough distance between benzene ring of the indanone and nitrobenzene enhance π - π stacking interaction, leading to the adaptation of the substrate in the helical chiral environment. R configuration at the α -C atom of substrate is more likely to generate. In contrast, the benzene moiety of the indanone is shielded bulky tribromobenzene moiety, thus making the (S) configuration disfavored and leading to the generation of the enantiomer in a minor amount. After formation of hemiacetale intermediate 19f-7 which involves inversion of configuration at the α -C atom through the transition state **19f-6**, fluoride anion is attacking on the epoxide ring (19f-8) to form a configuration of 19f-9 which further generated product 20f.^[12]

10. Reference

[1] Zhao, Y. & Truhlar, D.G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements. *Theor. Chem. Acc.* 2008, **120**, 215-241.

[2] Lee, C., Yang, W. & Parr, G. Development of the colle-salvetti correlation-energy formula into a functional of the electron density. *Phys. Rev. B* 1988, **37**, 785-789.

[3] Pritchard, B. P., Altarawy, D., Didier, B., Gibson, T. D., & Windus, T. L. A new basis set exchange: an open, up-to-date resource for the molecular sciences community. *J. Chem. Inf. Model.* 2019, **59**, 4814-4820.

[4] Fukui, K. Formulation of the reaction coordinate. J. Phys. Chem. 1970, 74, 4161-4163.

[5] Fukui, K. The path of chemical reactions - the IRC approach. Acc. Chem. Res. 1981, 14, 363-368.

[6] Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Petersson, G. A., Nakatsuji, H., Li, X., Caricato, M., Marenich, A. V., Bloino, J., Janesko, B. G., Gomperts, R., Mennucci, B., Hratchian, H. P., Ortiz, J. V., Izmaylov, A. F., Sonnenberg, J. L., Williams-Young, D., Ding, F., Lipparini, F., Egidi, F., Goings, J., Peng, B., Petrone, A., Henderson, T., Ranasinghe, D., Zakrzewski, V. G., Gao, J., Rega, N., Zheng, G., Liang, W., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Vreven, T., Throssell, K., Montgomery, J. A. Jr., Peralta, J. E., Ogliaro, F., Bearpark, M. J., Heyd, J. J., Brothers, E. N., Kudin, K. N., Staroverov, V. N., Keith, T. A., Kobayashi, R., Normand, J., Raghavachari, K., Rendell, A. P., Burant, J. C., Iyengar, S. S., Tomasi, J., Cossi, M., Millam, J. M., Klene, M., Adamo, C., Cammi, R., Ochterski, J. W., Martin, R. L., Morokuma, K., Farkas, O., Foresman, J. B. & Fox, D. J. Gaussian 16, Revision A.03, Gaussian: Wallingford, CT, USA, 2016.

[7] M. Uyanik, T. Yasui, and K. Ishihara, Enantioselective Kita oxidative spirolactonization catalyzed by in situ generated chiral hypervalent iodine(III) species. *Angew. Chem. Int. Ed.* 2010, 49, 2175–2177.

[8] M. Uyanik, T. Yasui and K. Ishihara, Chiral hypervalent organoiodine-catalyzed enantioselective oxidative spirolactonization of naphthol derivatives. *J. Org. Chem.* 2010, **82**, 11946–11953.

[9] N. Jain, S. Xu and M. A. Ciufolini, Asymmetric oxidative cycloetherification of naphtholic alcohols. *Chem. Eur. J.* 2017, 23: 4542–4546.

[10] D. Y. Zhang, L. Xu, H. Wu and L. Z. Gong, Chiral iodine-catalyzed dearomatizative spirocyclization for the enantioselective construction of an all-carbon stereogenic center. *Chem. Eur. J.* 2015, **21**, 10314–10317.

[11] H. Wu, Y. P. He, L. Xu, D. Y. Zhang and L. Z. Gong, Asymmetric organocatalytic direct C(sp²)-H/C(sp³)-H oxidative cross-coupling by chiral iodine reagent. *Angew. Chem. Int. Ed.* 2014, 53, 3466–3469.

[12] R. Pluta, P. E. Krach, L. Cavallo, L. Falivene and M. Rueping, Metal-free catalytic asymmetric fluorination of keto esters using a combination of hydrogen fluoride (HF) and oxidant: experiment and computation. *ACS Catal.* 2018, **8**, 2582–2588.

[13] M. Teiichi, F. Kiyotaka, T. Tadakazu, Y. Kazuyoshi and N. Masazumi, Synthesis and biological properties of novel sphingosine derivatives. *Bioorg. Med. Chem. Lett.* 2015, **15**, 1115–1119.

[14] J. F. Bower, P. Szeto and T. Gallagher, Enantiopure 1,4-benzoxazines via 1,2-cyclic sulfamidates. Synthesis of levofloxacin. *Org. Lett.* 2007, **9**, 3283–3286.

[15] E. Butler, L. Florentino, D. Cornut, G. Gomez-Campillos, H. Liu, A. C. Regan and E. J. Thomas, Synthesis of macrocyclic precursors of the vioprolides. *Org. Biomol. Chem.* 2018, **16**, 6935–6960.

[16] H. Zheng, L. Cai, M. Pan, M. Uyanik, K. Ishihara, and X. Xue, Catalyst-Substrate helical character matching determines the enantioselectivity in the Ishihara-Type iodoarenes catalyzed asymmetric kita-Dearomative spirolactonization. *J. Am. Chem. Soc.* 2023, **145**, 7301-7312.

[17] J. Wang, Y. Yuan, R. Xiong, D. Zhang-Negrerie, Y. Du, and K. Zhao, Phenyliodine bis(trifluoroacetate)-mediated oxidative C–C bond formation: Synthesis of 3-hydroxy-2-oxindoles and spirooxindoles from anilides. *Org. Lett.* 2012, **14**(**9**), 2210–2213.

11. X-ray crystallography analysis

Cat-8 (CCDC 2236217)



checkCIF/PLATON report

Structure factors have been supplied for datablock(s) mo_230104_zhj_mes

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: mo_230104_zhj_mes

Bond precision:	C-C = 0.0042 A	Wavelength=0.71073		
Cell:	a=13.3936(3) alpha=90	b=27.4740(6) beta=90	c=9.5840(2) gamma=90	
Temperature:	170 K			
	Calculated	Reported		
Volume	3526.68(13)	3526.68(1	3)	
Space group	P 21 21 2	P 21 21 2		
Hall group	P 2 2ab	P 2 2ab		
Moiety formula	C76 H81 I N4 O10 S	i2 C76 H81 I	N4 010 Si2	
Sum formula	C76 H81 I N4 O10 S	i2 C76 H81 I	N4 010 Si2	
Mr	1393.53	1393.52		
Dx,g cm-3	1.312	1.312		
Z	2	2		
Mu (mm-1)	0.549	0.549		
F000	1452.0	1452.0		
F000′	1451.95			
h,k,lmax	17,35,12	17,35,12		
Nref	8135[4559]	8123		
Tmin,Tmax	0.810,0.848	0.679,0.7	46	
Tmin'	0.768			
Correction metho AbsCorr = MULTI-	od= # Reported T Lim -SCAN	uits: Tmin=0.679 Tm	ax=0.746	
Data completenes	ss= 1.78/1.00	Theta(max) = 27.495	5	
R(reflections)= 0.0245(7539)			wR2(reflections)=	
S = 1.046	Npar= 47	0	0.0304(0123)	
The following ALERTS were generated. Each ALERT has the format **test-name_ALERT_alert-type_alert-level.** Click on the hyperlinks for more details of the test.

Alert level C			
PLAT220_ALERT_2_C NonSolvent Resd 1 C Ueq(max)/Ueq(min) Range	4.3		
PLAT222_ALERT_3_C NonSolvent Resd 1 H Uiso(max)/Uiso(min) Range	4.1		
PLAT911_ALERT_3_C Missing FCF Refl Between Thmin & STh/L= 0.600			
Alert level G			
PLAT002_ALERT_2_G Number of Distance or Angle Restraints on AtSite	13		
PLAT003_ALERT_2_G Number of Uiso or Uij Restrained non-H Atoms			
	-		

Ratio Ratio Report

Note Report Report

PLAT176_ALERT_4_G The CIF-Embedded .res File Contains SADI Records	15	Report			
PLAT178_ALERT_4_G The CIF-Embedded .res File Contains SIMU Records	1	Report			
PLAT188_ALERT_3_G A Non-default SIMU Restraint Value has been used	0.0200	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used	0.0400	Report			
PLAT301_ALERT_3_G Main Residue Disorder(Resd 1)	13%	Note			
PLAT791_ALERT_4_G Model has Chirality at C5 (Sohnke SpGr)	R	Verify			
PLAT791_ALERT_4_G Model has Chirality at C12 (Sohnke SpGr)	S	Verify			
PLAT860_ALERT_3_G Number of Least-Squares Restraints	111	Note			
PLAT910_ALERT_3_G Missing # of FCF Reflection(s) Below Theta(Min).	2	Note			
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L= 0.600	1	Note			
PLAT933_ALERT_2_G Number of HKL-OMIT Records in Embedded .res File	3	Note			
PLAT978_ALERT_2_G Number C-C Bonds with Positive Residual Density.	9	Info			
0 ALERT level A = Most likely a serious problem - resolve or explain	1				
0 ALERT level B = A potentially serious problem, consider carefully					
3 ALERT level C = Check. Ensure it is not caused by an omission or oversight					
22 ALERT level G = General information/check it is not something unex	spected				
0 ALERT type 1 CIF construction/syntax error, inconsistent or missing data					
5 ALERI type 2 indicator that the structure model may be wrong or deficient					
14 ALERT type 3 Indicator that the structure quality may be low					

Supplementary Figure 5. Single-crystal X-ray crystallography of Cat-8

5 ALERT type 4 Improvement, methodology, query or suggestion 1 ALERT type 5 Informative message, check

11 (CCDC 2236218)



checkCIF/PLATON report

Structure factors have been supplied for datablock(s) mo_230103_zhj_nh2_0m

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: mo_230103_zhj_nh2_0m

Bond precision:	C-C = 0.0087 A	Wavelength=0.71073	
Cell:	a=28.216(9) alpha=90	b=13.252(2) c=14.528(3) beta=90 gamma=90	
Temperature:	170 K		
	Calculated	Reported	
Volume	5432(2)	5432(2)	
Space group	P 21 21 2	P 21 21 2	
Hall group	P 2 2ab	P 2 2ab	
Moiety formula	C56 H60 I N4 O8 Si2	C56 H60 I N4 O8 Si2	
Sum formula	C56 H60 I N4 O8 Si2	C56 H61 I N4 O8 Si2	
Mr	1100.16	1101.16	
Dx,g cm-3	1.345	1.346	
Z	4	4	
Mu (mm-1)	0.690	0.690	
F000	2276.0	2280.0	
F000'	2275.63		
h,k,lmax	39,18,20	38,18,20	
Nref	16096[8799]	15884	
Tmin,Tmax	0.767,0.813	0.663,0.746	
Tmin'	0.718		
Correction metho AbsCorr = MULTI-	d= # Reported T Limit SCAN	ts: Tmin=0.663 Tmax=0.746	
Data completenes	s= 1.81/0.99	Cheta(max) = 30.159	
R(reflections)=	0.0439(11790)	wR2(reflections 0 1185(15884)) =
S = 1.035	Npar= 811	0.1103(15004)	

The following ALERTS were generated. Each ALERT has the format **test-name_ALERT_alert-type_alert-level**. Click on the hyperlinks for more details of the test.

```
Alert level C
PLAT041_ALERT_1_C Calc. and Reported SumFormula
                                                 Strings Differ
                                                                    Please Check
PLAT068_ALERT_1_C Reported F000 Differs from Calcd (or Missing)...
                                                                    Please Check
PLAT220_ALERT_2_C NonSolvent Resd 1 C Ueq(max)/Ueq(min) Range
                                                                       3.5 Ratio
PLAT234_ALERT_4_C Large Hirshfeld Difference C17
                                                                       0.17 Ang.
                                                   --C18
PLAT241_ALERT_2_C High 'MainMol' Ueq as Compared to Neighbors of
                                                                      C16 Check
PLAT241_ALERT_2_C High
                       'MainMol' Ueq as Compared to Neighbors of
                                                                       C18 Check
                       'MainMol' Ueq as Compared to Neighbors of
PLAT241_ALERT_2_C High
                                                                       C24 Check
PLAT241_ALERT_2_C High
                       'MainMol' Ueq as Compared to Neighbors of
                                                                       C47 Check
                       'MainMol' Ueq as Compared to Neighbors of
PLAT242_ALERT_2_C Low
                                                                       C10 Check
PLAT242_ALERT_2_C Low
                       'MainMol' Ueq as Compared to Neighbors of
                                                                       C14 Check
PLAT242_ALERT_2_C Low
                       'MainMol' Ueq as Compared to Neighbors of
                                                                       C35 Check
PLAT342_ALERT_3_C Low Bond Precision on C-C Bonds .....
                                                                   0.00868 Ang.
PLAT415_ALERT_2_C Short Inter D-H..H-X
                                           H1B
                                                   ..H36C
                                                                      2.05 Ang.
                                                              .
                                                  x,y,1+z =
                                                                 1_556 Check
PLAT420_ALERT_2_C D-H Bond Without Acceptor N1
                                                   --H1A
                                                                    Please Check
                                                               .
PLAT420_ALERT_2_C D-H Bond Without Acceptor N1
                                                    --H1B
                                                                     Please Check
                                                               .
PLAT420_ALERT_2_C D-H Bond Without Acceptor N3
                                                    --H3A
                                                                    Please Check
                                                               .
PLAT420_ALERT_2_C D-H Bond Without Acceptor N3
                                                    --H3B
                                                                    Please Check
PLAT934_ALERT_3_C Number of (Iobs-Icalc)/Sigma(W) > 10 Outliers ..
                                                                        1 Check
PLAT975_ALERT_2_C Check Calcd Resid. Dens. 1.08Ang From C7
                                                                       0.52 eA-3
                                                              .
```

```
Alert level G
```

FORMU01_ALERT_1_G There is a discrepancy between the atom counts in the _chemical_formula_sum and _chemical_formula_moiety. This is usually due to the moiety formula being in the wrong format. Atom count from _chemical_formula_sum: C56 H61 I1 N4 O8 Si2 Atom count from _chemical_formula_moiety:C56 H60 I1 N4 O8 Si2 FORMU01_ALERT_2_G There is a discrepancy between the atom counts in the _chemical_formula_sum and the formula from the _atom_site* data. Atom count from _chemical_formula_sum:C56 H61 I1 N4 O8 Si2 Atom count from the _atom_site data: C56 H60 I1 N4 O8 Si2 CELLZ01_ALERT_1_G Difference between formula and atom_site contents detected. CELLZ01_ALERT_1_G WARNING: H atoms missing from atom site list. Is this intentional? From the CIF: _cell_formula_units_Z 4 From the CIF: _chemical_formula_sum C56 H61 I N4 O8 Si2 TEST: Compare cell contents of formula and atom_site data atom Z*formula cif sites diff С 224.00 224.00 0.00 Н 244.00 240.00 4.00 т 4.00 4.00 0.00 N 16.00 16.00 0.00 0 32.00 32.00 0.00 Si 8.00 8.00 0.00 PLAT002_ALERT_2_G Number of Distance or Angle Restraints on AtSite 40 Note PLAT003_ALERT_2_G Number of Uiso or Uij Restrained non-H Atoms ... 39 Report PLAT007_ALERT_5_G Number of Unrefined Donor-H Atoms 4 Report PLAT172_ALERT_4_G The CIF-Embedded .res File Contains DFIX Records 1 Report PLAT176_ALERT_4_G The CIF-Embedded .res File Contains SADI Records 44 Report

```
PLAT178 ALERT 4 G The CIF-Embedded .res File Contains SIMU Records
                                                                            3 Report
                                                                       0.0200 Report
PLAT188_ALERT_3_G A Non-default SIMU Restraint Value has been used
PLAT188_ALERT_3_G A Non-default SIMU Restraint Value has been used
                                                                       0.0100 Report
PLAT188_ALERT_3_G A Non-default SIMU Restraint Value has been used
                                                                      0.0100 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                       0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                       0.0400 Report
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                       0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191_ALERT_3_G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT191 ALERT 3 G A Non-default SADI Restraint Value has been used
                                                                      0.0400 Report
PLAT301_ALERT_3_G Main Residue Disorder ......(Resd 1 )
                                                                         25% Note
PLAT367_ALERT_2_G Long? C(sp?)-C(sp?) Bond C7
                                                                        1.55 Ang.
                                                     - C8
PLAT410_ALERT_2_G Short Intra H...H Contact H28
                                                     ..H48
                                                                        2.08 Ang.
                                                     x,y,z =
                                                                   1_555 Check
PLAT410 ALERT 2 G Short Intra H...H Contact H34B
                                                      ..H40A
                                                                        2.03 Ang.
                                                     x,y,z =
                                                                   1 555 Check
PLAT410 ALERT 2 G Short Intra H...H Contact H44A
                                                     ..H46
                                                                        1.93 Ang.
                                                     x,y,z =
                                                                   1_555 Check
                                                     ..H44
                                            H37C
PLAT412 ALERT 2 G Short Intra XH3 .. XHn
                                                                        2.12 Ang.
                                                     x,y,z =
                                                                   1 555 Check
PLAT789_ALERT_4_G Atoms with Negative _atom_site_disorder_group #
                                                                          26 Check
PLAT791 ALERT 4 G Model has Chirality at C8
                                                    (Sohnke SpGr)
                                                                           S Verifv
PLAT791_ALERT_4_G Model has Chirality at C32
                                                    (Sohnke SpGr)
                                                                           R Verify
PLAT791_ALERT_4_G Model has Chirality at C33
                                                     (Sohnke SpGr)
                                                                           S Verify
PLAT811_ALERT_5_G No ADDSYM Analysis: Too Many Excluded Atoms ....
                                                                            ! Info
                                                                         585 Note
PLAT860_ALERT_3_G Number of Least-Squares Restraints .....
PLAT910_ALERT_3_G Missing # of FCF Reflection(s) Below Theta(Min).
                                                                           4 Note
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L= 0.600
                                                                          20 Note
PLAT933_ALERT_2_G Number of HKL-OMIT Records in Embedded .res File
                                                                           1 Note
PLAT978_ALERT_2_G Number C-C Bonds with Positive Residual Density.
                                                                           1 Info
   0 ALERT level A = Most likely a serious problem - resolve or explain
   0 ALERT level B = A potentially serious problem, consider carefully
  19 ALERT level C = Check. Ensure it is not caused by an omission or oversight
  53 ALERT level G = General information/check it is not something unexpected
   5 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
  24 ALERT type 2 Indicator that the structure model may be wrong or deficient
  32 ALERT type 3 Indicator that the structure quality may be low
   9 ALERT type 4 Improvement, methodology, query or suggestion
   2 ALERT type 5 Informative message, check
```

Supplementary Figure 6. Single-crystal X-ray crystallography of 11

12. ¹H, ¹³C, ¹⁹F spectrum of compounds

12.1 NMR spectra of intermediates and catalyst



Supplementary Figure 8. ¹³C NMR Spectrum of 9 (100 MHz, CDCl₃)



Supplementary Figure 9. ¹H NMR Spectrum of 10 (400 MHz, CDCl₃)



Supplementary Figure 10. ¹³C NMR Spectrum of 10 (100 MHz, CDCl₃)

88.03 89.03 80.03



Supplementary Figure 11. ¹H NMR Spectrum of 11 (400 MHz, CDCl₃)



Supplementary Figure 12. ¹³C NMR Spectrum of 11 (100 MHz, CDCl₃)



Supplementary Figure 13. ¹H NMR Spectrum of SI-13 (400 MHz, CDCl₃)



Supplementary Figure 14. ¹³C NMR Spectrum of SI-13 (100 MHz, CDCl₃)



Supplementary Figure 15. ¹H NMR Spectrum of Cat-1 (400 MHz, CDCl₃)



Supplementary Figure 16. ¹³C NMR Spectrum of Cat-1 (100 MHz, CDCl₃)



Supplementary Figure 17. ¹H NMR Spectrum of Cat-2 (400 MHz, CDCl₃)



Supplementary Figure 18. ¹³C NMR Spectrum of Cat-2 (100 MHz, CDCl₃)



4.0

3.5

3.0 2.5 1.5

2.0

0.5 0.0 -0

Supplementary Figure 19. ¹H NMR Spectrum of Cat-3 (400 MHz, CDCl₃)

6.5

7.0

8.0 7.5

5

10.0 9.5 9.0 8.5



Supplementary Figure 20. ¹³C NMR Spectrum of Cat-3 (100 MHz, CDCl₃)



Supplementary Figure 21. ¹H NMR Spectrum of Cat-4 (400 MHz, CDCl₃)



Supplementary Figure 22. ¹³C NMR Spectrum of Cat-4 (100 MHz, CDCl₃)



Supplementary Figure 23. ¹H NMR Spectrum of Cat-5 (400 MHz, CDCl₃)



Supplementary Figure 24. ¹³C NMR Spectrum of Cat-5 (100 MHz, CDCl₃)



Supplementary Figure 25. ¹H NMR Spectrum of Cat-6 (400 MHz, CDCl₃)



Supplementary Figure 26. ¹³C NMR Spectrum of Cat-6 (100 MHz, CDCl₃)



Supplementary Figure 27. ¹H NMR Spectrum of Cat-7 (400 MHz, CDCl₃)



Supplementary Figure 28. ¹³C NMR Spectrum of Cat-7 (100 MHz, CDCl₃)



Supplementary Figure 29. ¹⁹F NMR Spectrum of Cat-7 (376 MHz, CDCl₃)



Supplementary Figure 30.¹¹H NMR Spectrum of Cat-8 (400 MHz, CDCl₃)



Supplementary Figure 31. ¹³C NMR Spectrum of Cat-8 (100 MHz, CDCl₃)



Supplementary Figure 32. ¹H NMR Spectrum of Cat-9 (400 MHz, CDCl₃)



Supplementary Figure 33. ¹³C NMR Spectrum of Cat-9 (100 MHz, CDCl₃)



Supplementary Figure 34. ¹H NMR Spectrum of Cat-10 (400 MHz, CDCl₃)



Supplementary Figure 35. ¹³C NMR Spectrum of Cat-10 (100 MHz, CDCl₃)



Supplementary Figure 36. ¹H NMR Spectrum of Cat-11 (400 MHz, CDCl₃)



Supplementary Figure 37.¹³C NMR Spectrum of Cat-11 (100 MHz, CDCl₃)







Supplementary Figure 38. ¹H NMR Spectrum of Cat-12 (400 MHz, CDCl₃)



Supplementary Figure 39. ¹³C NMR Spectrum of Cat-12 (100 MHz, CDCl₃)



Supplementary Figure 40. ¹H NMR Spectrum of Cat-13 (400 MHz, CDCl₃)



Supplementary Figure 41. ¹³C NMR Spectrum of Cat-13 (100 MHz, CDCl₃)



Supplementary Figure 42. ¹H NMR Spectrum of Cat-14 (400 MHz, CDCl₃)



Supplementary Figure 43. ¹³C NMR Spectrum of Cat-14 (100 MHz, CDCl₃)



Supplementary Figure 44. ¹H NMR Spectrum of Cat-15 (400 MHz, CDCl₃)



Supplementary Figure 45. ¹³C NMR Spectrum of Cat-15 (100 MHz, CDCl₃)



Supplementary Figure 46. ¹⁹F NMR Spectrum of Cat-15 (376 MHz, CDCl₃)



Supplementary Figure 47. ¹H NMR Spectrum of Cat-16 (400 MHz, CDCl₃)



Supplementary Figure 48. ¹³C NMR Spectrum of Cat-16 (100 MHz, CDCl₃)



Supplementary Figure 49. ¹H NMR Spectrum of Cat-17 (400 MHz, CDCl₃)



Supplementary Figure 50. ¹³C NMR Spectrum of Cat-17 (100 MHz, CDCl₃)



Supplementary Figure 51. ¹H NMR Spectrum of Cat-18 (400 MHz, CDCl₃)



Supplementary Figure 52. ¹³C NMR Spectrum of Cat-18 (100 MHz, CDCl₃)



Supplementary Figure 53. ¹⁹F NMR Spectrum of Cat-18 (376 MHz, CDCl₃)



Supplementary Figure 54. ¹H NMR Spectrum of Cat-19 (400 MHz, CDCl₃)



Supplementary Figure 55. ¹³C NMR Spectrum of Cat-19 (100 MHz, CDCl₃)



Supplementary Figure 56. ¹H NMR Spectrum of Cat-20 (400 MHz, CDCl₃)



Supplementary Figure 57.¹³C NMR Spectrum of Cat-20 (100 MHz, CDCl₃)



Supplementary Figure 58. ¹H NMR Spectrum of Cat-21 (400 MHz, CDCl₃)



Supplementary Figure 59. ¹³C NMR Spectrum of Cat-21 (100 MHz, CDCl₃)



Supplementary Figure 60. ¹H NMR Spectrum of Cat-25 (400 MHz, CDCl₃)



Supplementary Figure 61. ¹³C NMR Spectrum of Cat-25 (100 MHz, CDCl₃)



Supplementary Figure 62. ¹¹H NMR Spectrum of Cat-26 (400 MHz, CDCl₃)



Supplementary Figure 63. ¹³C NMR Spectrum of Cat-26 (100 MHz, CDCl₃)



Supplementary Figure 64. ¹H NMR Spectrum of Cat-27 (400 MHz, CDCl₃)

21.1



Supplementary Figure 65. ¹³C NMR Spectrum of Cat-27 (100 MHz, CDCl₃)



Supplementary Figure 66. ¹⁹F NMR Spectrum of Cat-27 (376 MHz, CDCl₃)



Supplementary Figure 67. ¹H NMR Spectrum of Cat-28 (400 MHz, CDCl₃)



Supplementary Figure 68. ¹³C NMR Spectrum of Cat-28 (100 MHz, CDCl₃)



Supplementary Figure 69. ¹H NMR Spectrum of Cat-29 (400 MHz, CDCl₃)



Supplementary Figure 70.¹³C NMR Spectrum of Cat-29 (100 MHz, CDCl₃)




Supplementary Figure 71. ¹H NMR Spectrum of Cat-30 (400 MHz, CDCl₃)



Supplementary Figure 72. ¹³C NMR Spectrum of Cat-30 (100 MHz, CDCl₃)



Supplementary Figure 73. ¹H NMR Spectrum of Cat-31 (400 MHz, CDCl₃)



Supplementary Figure 74. ¹³C NMR Spectrum of Cat-31 (100 MHz, CDCl₃)



Supplementary Figure 75. ¹H NMR Spectrum of Cat-32 (400 MHz, CDCl₃)



Supplementary Figure 76. ¹³C NMR Spectrum of Cat-32 (100 MHz, CDCl₃)





Supplementary Figure 77. ¹H NMR Spectrum of Cat-33 (400 MHz, CDCl₃)



Supplementary Figure 78. ¹³C NMR Spectrum of Cat-33 (100 MHz, CDCl₃)



Supplementary Figure 79. ¹H NMR Spectrum of Cat-34 (400 MHz, CDCl₃)



Supplementary Figure 80. ¹³C NMR Spectrum of Cat-34 (100 MHz, CDCl₃)



Supplementary Figure 81. ¹H NMR Spectrum of Cat-35 (400 MHz, CDCl₃)



Supplementary Figure 82. ¹³C NMR Spectrum of Cat-35 (100 MHz, CDCl₃)





Supplementary Figure 83. ¹H NMR Spectrum of Cat-36 (400 MHz, CDCl₃)



Supplementary Figure 84. ¹³C NMR Spectrum of Cat-36 (100 MHz, CDCl₃)



Supplementary Figure 85. ¹H NMR Spectrum of Cat-37 (400 MHz, CDCl₃)



Supplementary Figure 86. ¹³C NMR Spectrum of Cat-37 (100 MHz, CDCl₃)



Supplementary Figure 87. ¹H NMR Spectrum of Cat-38 (400 MHz, CDCl₃)



Supplementary Figure 88. ¹³C NMR Spectrum of Cat-38 (100 MHz, CDCl₃)



Supplementary Figure 89. ¹H NMR Spectrum of Cat-39 (400 MHz, CDCl₃)



Supplementary Figure 90. ¹³C NMR Spectrum of Cat-39 (100 MHz, CDCl₃)



Supplementary Figure 91. ¹H NMR Spectrum of Cat-40 (400 MHz, CDCl₃)



Supplementary Figure 92. ¹³C NMR Spectrum of Cat-40 (100 MHz, CDCl₃)



Supplementary Figure 93. ¹H NMR Spectrum of Cat-41 (400 MHz, CDCl₃)



Supplementary Figure 94. ¹³C NMR Spectrum of Cat-41 (100 MHz, CDCl₃)



Supplementary Figure 95. ¹H NMR Spectrum of Cat-43 (400 MHz, CDCl₃)



Supplementary Figure 96. ¹³C NMR Spectrum of Cat-43 (100 MHz, CDCl₃)



Supplementary Figure 97. ¹H NMR Spectrum of Cat-45 (400 MHz, CDCl₃)



Supplementary Figure 98. ¹³C NMR Spectrum of Cat-45 (100 MHz, CDCl₃)





Supplementary Figure 99. ¹H NMR Spectrum of Cat-47 (400 MHz, CDCl₃)



Supplementary Figure 100. ¹³C NMR Spectrum of Cat-47 (100 MHz, CDCl₃)



Supplementary Figure 101. ¹H NMR Spectrum of Cat-48 (400 MHz, CDCl₃)



Supplementary Figure 102. ¹³C NMR Spectrum of Cat-48 (100 MHz, CDCl₃)



Supplementary Figure 103. ¹H NMR Spectrum of Cat-49 (400 MHz, CDCl₃)



Supplementary Figure 104. ¹³C NMR Spectrum of Cat-49 (100 MHz, CDCl₃)

12.2 NMR spectra of product



12.2.1 Spectrum of enantioselective oxidative dearomatization

Supplementary Figure 106. ¹³C NMR Spectrum of 13a (100 MHz, CDCl₃)

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)



Supplementary Figure 107. ¹H NMR Spectrum of 13b (400 MHz, CDCl₃)



Supplementary Figure 108. ¹³C NMR Spectrum of 13b (100 MHz, CDCl₃)



Supplementary Figure 109. ¹H NMR Spectrum of 13c (400 MHz, CDCl₃)



Supplementary Figure 110. ¹³C NMR Spectrum of 13c (100 MHz, CDCl₃)



Supplementary Figure 111. ¹H NMR Spectrum of 13d (400 MHz, CDCl₃)



Supplementary Figure 112. ¹³C NMR Spectrum of 13d (100 MHz, CDCl₃)







Supplementary Figure 114. ¹³C NMR Spectrum of 13e (100 MHz, CDCl₃)



Supplementary Figure 115. ¹H NMR Spectrum of 13f (400 MHz, CDCl₃)



Supplementary Figure 116. ¹³C NMR Spectrum of 13f (100 MHz, CDCl₃)



Supplementary Figure 117. ¹H NMR Spectrum of 13g (400 MHz, CDCl₃)



Supplementary Figure 118. ¹³C NMR Spectrum of 13g (100 MHz, CDCl)



Supplementary Figure 119. ¹H NMR Spectrum of 13h (400 MHz, CDCl₃)



Supplementary Figure 120. ¹³C NMR Spectrum of 13h (100 MHz, CDCl₃)



Supplementary Figure 121. ¹H NMR Spectrum of 13i (400 MHz, CDCl₃)



Supplementary Figure 122. ¹³C NMR Spectrum of 13i (100 MHz, CDCl₃)



Supplementary Figure 123. ¹¹H NMR Spectrum of 13j (400 MHz, CDCl₃)



Supplementary Figure 124. ¹³C NMR Spectrum of 13j (100 MHz, CDCl₃)



Supplementary Figure 125. ¹H NMR Spectrum of 13k (400 MHz, CDCl₃)



Supplementary Figure 126. ¹³C NMR Spectrum of 13k (100 MHz, CDCl₃)



Supplementary Figure 127. ¹H NMR Spectrum of 13l (400 MHz, CDCl₃)



Supplementary Figure 128. ¹³C NMR Spectrum of 13l (100 MHz, CDCl₃)



Supplementary Figure 129. ¹H NMR Spectrum of 13m (400 MHz, CDCl₃)



Supplementary Figure 130. ¹³C NMR Spectrum of 13m (100 MHz, CDCl₃)



Supplementary Figure 131. ¹H NMR Spectrum of 13n (400 MHz, CDCl₃)



Supplementary Figure 132. ¹³C NMR Spectrum of 13n (100 MHz, CDCl₃)



Supplementary Figure 133. ¹H NMR Spectrum of 130 (400 MHz, CDCl₃)



Supplementary Figure 134. ¹³C NMR Spectrum of 13o (100 MHz, CDCl₃)



Supplementary Figure 135. ¹H NMR Spectrum of 14a (400 MHz, CDCl₃)



Supplementary Figure 136. ¹³C NMR Spectrum of 14a (100 MHz, CDCl₃)



Supplementary Figure 137. ¹H NMR Spectrum of 14b (400 MHz, CDCl₃)



Supplementary Figure 138. ¹³C NMR Spectrum of 14b (100 MHz, CDCl₃)





Supplementary Figure 139. ¹H NMR Spectrum of 14c (400 MHz, CDCl₃)



Supplementary Figure 140. ¹³C NMR Spectrum of 14c (100 MHz, CDCl₃)





Supplementary Figure 141. ¹H NMR Spectrum of 14d (400 MHz, CDCl₃)



Supplementary Figure 142. ¹³C NMR Spectrum of 14d (100 MHz, CDCl₃)




Supplementary Figure 143. ¹H NMR Spectrum of 14e (400 MHz, CDCl₃)



Supplementary Figure 144. ¹³C NMR Spectrum of 14e (100 MHz, CDCl₃)





Supplementary Figure 145. ¹H NMR Spectrum of 14f (400 MHz, CDCl₃)



Supplementary Figure 146. ¹³C NMR Spectrum of 14f (100 MHz, CDCl₃)





Supplementary Figure 147. ¹H NMR Spectrum of 14g (400 MHz, CDCl₃)



Supplementary Figure 148. ¹³C NMR Spectrum of 14g (100 MHz, CDCl₃)



Supplementary Figure 149. ¹H NMR Spectrum of 14h (400 MHz, CDCl₃)



Supplementary Figure 150. ¹³C NMR Spectrum of 14h (100 MHz, CDCl₃)



Supplementary Figure 151. ¹H NMR Spectrum of 14i (400 MHz, CDCl₃)



Supplementary Figure 152. ¹³C NMR Spectrum of 14i (100 MHz, CDCl₃)



Supplementary Figure 154. ¹³C NMR Spectrum of 14j (100 MHz, CDCl₃)

12.2.2 Spectrum of oxidative spirolactonization



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

Supplementary Figure 156. ¹³C NMR Spectrum of 16a (100 MHz, CDCl₃)



Supplementary Figure 157. ¹H NMR Spectrum of 16b (400 MHz, CDCl₃)



Supplementary Figure 158. ¹³C NMR Spectrum of 16b (100 MHz, CDCl₃)



Supplementary Figure 159. ¹H NMR Spectrum of 16c (400 MHz, CDCl₃)



Supplementary Figure 160. ¹³C NMR Spectrum of 16c (100 MHz, CDCl₃)



Supplementary Figure 161. ¹H NMR Spectrum of 16d (400 MHz, CDCl₃)



Supplementary Figure 162. ¹³C NMR Spectrum of 16d (100 MHz, CDCl₃)



Supplementary Figure 163. ¹H NMR Spectrum of 16e (400 MHz, CDCl₃)



Supplementary Figure 164. ¹³C NMR Spectrum of 16e (100 MHz, CDCl₃)



Supplementary Figure 165. ¹H NMR Spectrum of 16f (400 MHz, CDCl₃)



Supplementary Figure 166. ¹³C NMR Spectrum of 16f (100 MHz, CDCl₃)

12.2.3 Spectrum of direct C(sp²)-H/C(sp³)-H cross-coupling



Supplementary Figure 168. 13 C NMR Spectrum of 18a (100 MHz, CDCl₃) 193



Supplementary Figure 169. ¹H NMR Spectrum of 18b (400 MHz, CDCl₃)



Supplementary Figure 170. ¹³C NMR Spectrum of 18b (100 MHz, CDCl₃)



Supplementary Figure 171. ¹H NMR Spectrum of 18c (400 MHz, CDCl₃)



Supplementary Figure 172. ¹³C NMR Spectrum of 18c (100 MHz, CDCl₃)



Supplementary Figure 173. ¹H NMR Spectrum of 18d (400 MHz, CDCl₃)



Supplementary Figure 174. ¹³C NMR Spectrum of 18d (100 MHz, CDCl₃)





Supplementary Figure 175. ¹H NMR Spectrum of 18e (400 MHz, CDCl₃)



Supplementary Figure 176. ¹³C NMR Spectrum of 18e (100 MHz, CDCl₃)



Supplementary Figure 177. ¹H NMR Spectrum of 18f (400 MHz, CDCl₃)



Supplementary Figure 178. ¹³C NMR Spectrum of 18f (100 MHz, CDCl₃)

12.2.4 Spectrum of oxidative fluorination of keto esters



Supplementary Figure 180. ¹³C NMR Spectrum of 20a (100 MHz, CDCl₃) 199



Supplementary Figure 181. ¹⁹F NMR Spectrum of 20a (376 MHz, CDCl₃)



Supplementary Figure 182. ¹H NMR Spectrum of 20b (400 MHz, CDCl₃)



Supplementary Figure 183. ¹³C NMR Spectrum of 20b (100 MHz, CDCl₃)





Supplementary Figure 184. ¹⁹F NMR Spectrum of 20b (376 MHz, CDCl₃)



Supplementary Figure 185. ¹H NMR Spectrum of 20c (400 MHz, CDCl₃)



Supplementary Figure 186. ¹³C NMR Spectrum of 20c (100 MHz, CDCl₃)



Supplementary Figure 187. ¹⁹F NMR Spectrum of 20c (376 MHz, CDCl₃)



Supplementary Figure 188. ¹H NMR Spectrum of 20d (400 MHz, CDCl₃)



Supplementary Figure 189. ¹³C NMR Spectrum of 20d (100 MHz, CDCl₃)

CI CO₂Ad

20d



Supplementary Figure 190. ¹⁹F NMR Spectrum of 20d (376 MHz, CDCl₃)



3.81 3.77 3.77 3.76 3.76 3.76 3.46 3.46 3.46 3.40



Supplementary Figure 191. ¹H NMR Spectrum of 20e (400 MHz, CDCl₃)



Supplementary Figure 192. ¹³C NMR Spectrum of 20e (100 MHz, CDCl₃)



Supplementary Figure 193. ¹⁹F NMR Spectrum of 20e (376 MHz, CDCl₃)



Supplementary Figure 194. ¹H NMR Spectrum of 20f (400 MHz, CDCl₃)



Supplementary Figure 195. ¹³C NMR Spectrum of 20f (100 MHz, CDCl₃)





Supplementary Figure 196. ¹⁹F NMR Spectrum of 20f (376 MHz, CDCl₃)



Supplementary Figure 197. ¹H NMR Spectrum of 20g (400 MHz, CDCl₃)



Supplementary Figure 198. ¹³C NMR Spectrum of 20g (100 MHz, CDCl₃)



Supplementary Figure 199. ¹⁹F NMR Spectrum of 20g (376 MHz, CDCl₃)



Supplementary Figure 200. ¹H NMR Spectrum of 20h (400 MHz, CDCl₃)



Supplementary Figure 201. ¹³C NMR Spectrum of 20h (100 MHz, CDCl₃)

Br∖ CO₂Me 20h



Supplementary Figure 202. ¹⁹F NMR Spectrum of 20h (376 MHz, CDCl₃)



Supplementary Figure 204. ¹³C NMR Spectrum of 20i (100 MHz, CDCl₃)



Supplementary Figure 205. ¹⁹F NMR Spectrum of 20i (376 MHz, CDCl₃)



Supplementary Figure 206. ¹H NMR Spectrum of 20j (400 MHz, CDCl₃)



Supplementary Figure 207. ¹³C NMR Spectrum of 20j (100 MHz, CDCl₃)

CO₂Me MeO 20j

-100 f1 (ppm) -110 -180 -190 -2 5 -10 -20 -90 -120 -130 -140 -150 -160 -170 -30 -40 -50 -60 -70 -80

Supplementary Figure 208. ¹⁹F NMR Spectrum of 20j (376 MHz, CDCl₃)







Supplementary Figure 210. ¹³C NMR Spectrum of 20k (100 MHz, CDCl₃)



Supplementary Figure 211. ¹⁹F NMR Spectrum of 20i (376 MHz, CDCl₃)